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This study describes the immunological characterization of a novel primary 
epithelial cell-type from the human umbilical cord.  
Two types of cells can be derived from the umbilical cord lining membrane, 
termed cord lining epithelial cells (CLECs) and cord lining mesenchymal cells (CLMCs). 
Preliminary immunophenotyping showed that CLECs but not CLMCs express significant 
levels of HLA-G isoforms and HLA-E, two MHC-Ib molecules with immunosuppressive 
functions which mediate immune tolerance during pregnancy.  
 Further detailed immunological analysis using in vitro/ex vivo assays (including 
mixed leukocyte reactions) showed that CLECs inhibit human allogeneic and mitogen 
stimulated T-lymphocyte responses with a concomitant reduction in pro-inflammatory 
cytokines. Using a transwell co-culture system, it was demonstrated that these 
immunoregulatory effects were mediated by soluble factors secreted by CLECs, in a 
dose-dependent manner. HLA-G functional studies showed that the effects of CLEC 
secreted products could be inhibited by an HLA-G blocking antibody, thus demonstrating 
a significant and important role for soluble HLA-G. However, this immunoregulation by 
CLECs did not involve induction of T cell apoptosis or expansion of regulatory T cells.  
In in vivo studies in immunocompetent mice, transplanted CLECs could be 
maintained for extended periods while acute xeno-rejection rapidly destroyed primary 
keratinocytes, a control human epithelial cell type. Viable CLECs could be retrieved from 
the subcutaneous transplant site two weeks after original transplantation and re-cultured. 
Additionally, CLECs delayed the rejection of keratinocytes and extended their survival 
  xiv
when co-transplanted, indicating an ability to protect adjacent human cell types that 
would otherwise be rejected if transplanted alone.  
In a preliminary study of ex vivo gene therapy, CLECs transduced with a modified 
human proinsulin gene were transplanted intra-peritoneally into streptozotocin (STZ) 
induced diabetic mice, resulting in significantly lower levels of serum glucose compared 
to control mice. 
 This is the first detailed study in which the immunological properties of CLECs 
have been comprehensively investigated and a potential therapeutic application for 
CLECs has been tested in the treatment of a type 1 diabetes mouse model.  
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Chapter 1  Introduction 
1.1 Background 
1.1.1 Prevalence of diabetes mellitus 
Diabetes mellitus is a disease which can cause many complications leading to 
morbidity and mortality. Despite the availability of treatment, diabetes remains a major 
cause of premature illness and death in most countries, mainly through the increased risk 
of cardiovascular disease. Other complications such as chronic nephropathy, retinal 
damage and neuropathy, lead to conditions as severe as kidney failure, blindness and 
limb amputation.  
The frequency of diabetes is rising dramatically all over the world and has been 
recognized as a global epidemic. In 2000, according to the World Health Organization, at 
least 171 million people worldwide were suffering from diabetes, or 2.8% of the 
population (Wild et al. 2004). By then the total number of people with diabetes were 
estimated to rise to 4.4%, 366 million in 2030. But more recent estimates in 2009 
reported much more rapidly increasing prevalence than expected. The incidence of 
diabetes among adults was estimated to have reached 6.4%, affecting 285 million adults 
in 2010, and was projected to increase to 7.7% and 439 million by 2030 (Shaw et al. 
2009). Diabetes clearly poses huge social and financial burdens globally.  
When it was first purified in 1921, insulin was hailed as the cure for diabetes. 
Insulin replacement therapy is still the primary treatment for type 1 diabetes. It is the 
most effective diabetes treatment for hyperglycemia and is sometimes required in the 
treatment of type 2 diabetes as well. However, patterns of physiologic insulin release are 
very hard to mimic with injections of exogenous insulin. Even with the use of insulin 
premixes and analogs and close glucose monitoring, the risks of postprandial 
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hyperglycemia and hypoglycemia are present and long-term complications may still 
develop.  
 
1.1.2 Pancreas and islet transplantation 
Transplantation of organs and tissues from one body to another or from one site of 
the body to another site, serves the purpose of replacing the recipient’s damaged or 
absent organ/tissue. Pancreas transplantation has been performed to ameliorate diabetes 
and establish long-term insulin independence. The success with pancreas transplantation 
shows proof of concept for β-cell replacement therapies. Transplantation of isolated islets 
has also been used as an alternative to whole pancreas transplantation, which involves 
much less invasive surgical procedures. However, both pancreatic and islet 
transplantations are limited by the lack of suitable donor organs/tissues.  
The relatively new discipline of cell transplantation has the potential to fill the 
gap between increasing need of donor organs/tissues and extreme shortage in their supply. 
Additionally, cell transplantation has the versatility with ease of ex vivo culture and 
manipulation, potentially incorporating gene therapy into the transplantation approach. 
Hence, novel strategies of using cell therapy and/or gene therapy for the treatment of 
diabetes are being studied intensively.  
For the treatment of type 1 diabetes, the areas of cell therapy and gene therapy are 
closely interconnected with regard to the need to establish insulin production. Three 
approaches have been attempted with varying degrees of success, which are stem cell 




1.1.3 Cell therapy 
 Stem cells can be differentiated in vitro to produce insulin-expressing cells with 
molecular characteristics resembling bona fide β-cells. Based on understandings of the 
fundamentals of normal embryonic development, protocols have been developed to direct 
the differentiation of embryonic stem cells (ESCs) into definitive endoderm and then into 
pancreatic progenitors expressing PDX-1. Subsequently, differentiated cells with insulin, 
glucagon, somatostatin, pancreatic polypeptide and ghrelin expressions could be obtained. 
ESC-derived insulin-producing cells have been used to treat streptozocin induced diabetic 
mice. When transplanted, they could prolong survival of the recipients (Eshpeter et al. 
2008) and secreted insulin in response to glucose in vivo (Kroon et al. 2008).  
Induced pluripotent stem cells (iPSCs) have been generated from adult fibroblasts 
by overexpression of four transcription factors Oct-3/4, SOX2, c-Myc, and Klf4 
(Takahashi et al. 2007). Recent development has enabled reprogramming of various types 
of adult somatic cells into iPSCs (Aasen et al. 2008; Aoi et al. 2008). It has also become 
possible to generate iPSCs without the use of oncogenes (Nakagawa et al. 2008) or viral 
vectors (Okita et al. 2008). IPSCs are an exciting potential alternative to ESCs. They are 
thought to have similar differentiation potentials with ESCs. Studies using iPSCs to 
generate insulin-producing cells are emerging. IPSCs could be used to generate islet-like 
clusters in vitro which expressed insulin (Tateishi et al. 2008). A recent study reported 
that iPSC-derived β-cell like cells could be transplanted to achieve long-term glycemic 
control in two mouse models of type 1 and 2 diabetes (Alipio et al. 2010). However, 
interpretation and comparison of these results have been difficult due to the many 
different cell types and protocols used to generate iPSCs.  
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Based on these promising results, the possibility of inducing ESCs and iPSCs to 
differentiate into fully functional β-cells is attractive. However, better understanding is 
still required for the intermediate stages involved in the complicated pathways of 
pancreatic development. Criteria for the evaluation of β-cell functionality also need to be 
defined. Thus far, ESCs and iPSCs have not been used in any clinical therapies and 
progress to clinical use has been hampered by the possibility of potential tumorigenesis 
after transplantation.  
Adult stem cells or progenitor cells could also be used for generation of insulin-
producing cells through differentiation or transdifferentiation. Studies in this field are 
abundant. Therapeutic success has been reported mainly with multipotent mesenchymal 
stem cells (MSCs). MSCs derived from bone marrow (Gabr et al. 2008), Wharton’s jelly 
(Chao et al. 2008) and adipose tissues (Chandra et al. 2009) have been differentiated into 
insulin producing clusters. Successful applications of those MSC-derived insulin-
producing cells in treatment of diabetic animals have also been reported. Problems that 
remain difficult include sufficient insulin content comparable to normal islets and a rapid 
physiological response to glucose levels.  
Undifferentiated MSCs also have been transplanted to improve the outcome of 
diabetes, possibly by promoting β-cells survival and regeneration (Hess et al. 2003; Lee 
et al. 2006). The role of MSCs in these studies has not been fully understood. The 
possibility of in vivo transdifferentiation of MSCs into insulin-producing cells remains 
debatable (Ianus et al. 2003; Lechner et al. 2004). The beneficial effects may be 
associated with secretion of factors which stimulate tissue repair and/or vascularization, 
or modulation of inflammatory responses. A more detailed review of MSCs can be found 
in the next chapter.  
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Transdifferentiation from organ-specific progenitor cells has also been explored, 
based on the hypothesis that their assignment to a specific differentiation pathway might 
require fewer steps than the less committed stem cells to differentiate into β-cells. Such 
transdifferentiation protocols have been developed for pancreatic duct epithelial cells 
(Bonner-Weir et al. 2000; Yatoh et al. 2007), liver cells (Zalzman et al. 2005) and 
pancreatic exocrine cells (Baeyens et al. 2005; Zhou et al. 2008a). One outstanding 
problem is difficulty in obtaining sufficient cell numbers in order to treat diabetic patients.  
 
1.1.4 Gene therapy 
Gene therapies of diabetes have explored the use of insulin gene and a number of 
genes encoding transcription factors which are associated with pancreatic and β-cell 
development. For direct in vivo gene therapy, these genes can be introduced alone or in 
combination into liver or pancreatic cells, either to express insulin directly or to induce 
transdifferentiation in vivo (Ren et al. 2007; Zhou et al. 2008a). For ex vivo gene therapy, 
autologous hepatocytes have been used successfully in preclinical model of pigs (Chen et 
al. 2008). Being surgically invasive, this approach has not been applied clinically. The 
safety assessment of genetic manipulation is ongoing. Site-directed integration techniques 
are being developed to avoid insertional mutagenesis. To achieve long-term transgene 
expression, problems such as loss of episomal vectors or undesired silencing of the 
transgenes need to be addressed.  
 
1.1.5 Immunosuppression 
Notably, both pancreas and islet transplantation require life-long 
immunosuppression, to prevent the immune system from rejecting and destroying the 
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transplant. Current immunosuppressive regimens are usually expensive and may increase 
the risk for specific malignancies and opportunistic infections. In addition, some of these 
drugs may also impair normal islet function and/or insulin action, or have side effects of 
nephrotoxicity (Hirshberg et al. 2003). Most of the cell sources considered for β-cell 
replacement therapy would suffer from the same problem, unless autologous cells are 
used. The major obstacle of using autologous cells is to obtain sufficient number of cells, 
which may potentially be solved by the reprogramming of somatic cells into iPSCs. 
However, as mentioned earlier, due to the risk of potential tumorigenesis, iPSCs may also 
be a long way from clinical application.  
 In addition, the pathophysiology of type 1 diabetes involves autoimmune 
processes against islet cells. Any β-cell replacement therapy would have to address this 
problem, which may not be solved by autologous cell transplantation. Besides the 
immunosuppressive drugs currently used, alternative cell-based approaches are being 
developed to modulate the immune system. Proof-of-principle studies with bone marrow 
derived MSCs suggest that transplantation of cells with immune modulatory properties 
can be a new therapeutic strategy for the treatment of type 1 diabetes (Abdi et al. 2008).  
 
1.2 Present study 
 In this study, a novel cell type from human umbilical cord lining membrane, 
which potentially possesses immunomodulatory properties, were characterized. The aims 
of the present study were: 
1. To characterize and define the cord lining cells in terms of major 
histocompatibility complex (MHC) and other molecular marker expressions 
including the immunosuppressive molecules HLA-G and HLA-E. 
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2. To study the immunological properties of cord lining cells using in vitro assays of 
T lymphocyte activation and dendritic cell maturation.  
3. To investigate the mechanisms of cord lining cell and T lymphocyte interactions.  
4. To study the immunogenicity of cord lining cells in vivo using an 
immunocompetent mouse model.  
5. To test the therapeutic application of cord lining cells in ex vivo insulin gene 
therapy using a streptozocin (STZ) induced type 1 diabetic mouse model.  
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Chapter 2  Literature Review 
All organ and cell transplantation done at present, other than between identical 
twins, has the problem of immunorejection by the recipient. With the use of 
immunosuppressant drugs, this problem is attenuated and controlled but not solved. Stem 
cells, which are being studied intensively as a potential source for transplantation, can be 
grown into virtually unlimited numbers and have the potential of differentiating into 
mature cells with characteristics and functions resembling the target cell types. Hence, 
stem cells had been considered as a superior cell source for transplantation. However, 
stem cell transplantation is faced with the same key challenge in transplantation, which is 
immune rejection.  
The following literature review will focus on the immunogenicity of various types 
of stem cells and progenitor cells. Based on their time of isolation during ontogenesis, 
these cells can be loosely classified into three broad categories: embryonic, fetal/neonatal 
and adult. I will review first embryonic stem cells, induced pluripotent stem cells and 
then the adult bone marrow derived stem cells, which are well known and best studied for 
their immune modulatory properties. Finally, cells from fetal tissues and pregnancy 
related tissues, i.e. amniotic fluid, placenta and umbilical cord, will be reviewed as the 
most relevant cell sources related to the topic of this thesis.  
 
2.1 Embryonic stem cells 
 Embryonic stem cells (ESCs) are pluripotent cells derived from the inner cell 
mass of the blastocyst. Pluripotent diploid ESCs have been derived from the mouse 
blastocyst in 1981 (Evans et al. 1981; Martin 1981). Professor Ariff Bongso’s group in 
National University of Singapore was the first to discover stem cells from human 
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preimplantation embryos in 1994 (Bongso et al. 1994). Embryonic stem cell lines were 
then successfully established by James Thomson’s group in 1998 (Thomson et al. 1998). 
The ESCs have been valued not only as the model for developmental biology or for drug 
screening, but also as a potential source of transplantable cells for many different diseases 
in regenerative medicine. In embryo development, ESCs give rise to all types of cells that 
make up the human body. Their pluripotency can be demonstrated in vitro by embryoid 
bodies (EBs) spontaneously formed in non-adherent ESC cultures which comprise all 
three germ layers (Itskovitz-Eldor et al. 2000), or in vivo by teratoma formation in 
immune compromised animals (Thomson et al. 1998). Their directed in vitro 
differentiation for the generation of specific cell types has been extensively explored by 
many research groups. Given the proper stimuli, the ESCs have been successfully 
differentiated into derivatives of all 3 germ layers, including neural precursors (Reubinoff 
et al. 2001; Zhang et al. 2001; Hong et al. 2008), endothelial cells (Levenberg et al. 2002), 
cardiomyocytes (Kehat et al. 2001; Xu et al. 2002) , hematopoietic precursors (Chadwick 
et al. 2003; Ng et al. 2005), hepatocyte-like cells (Rambhatla et al. 2003; Duan et al. 
2007), pancreatic/insulin-producing cells (D’Amour et al. 2006; Jiang et al. 2007), etc.  
However, in spite of much effort spent and much progress achieved in the 
development of ESC isolation and culture techniques, which include ES derivation from 
single blastomeres avoiding destruction of the embryo (Klimanskaya et al. 2006), and 
serum-free, feeder layer-free ESC cultures which avoids contamination with non-human 
factors (Klimanskaya et al. 2005), no clinical treatments using ESCs have been approved 
and applied to date. The possibility of teratoma formation in an immunosuppressed host 
has been the main barrier. Some ethical issues have also been a problem. 
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Some studies have investigated the immunogenicity of embryonic stem cells. Due 
to the low MHC I and no MHC II expression in ESCs (Drukker et al. 2002), and the fact 
that the embryo despite having 50% foreign paternal genetic material, is tolerated by the 
maternal system, some researchers have hypothesized that ESCs may possess immune-
privileged properties. Indeed, mouse ESCs have been shown to survive for many weeks 
post-transplantation in allogeneic immunocompetent mice (Koch et al. 2008), as well as 
in rats (Min et al. 2003) and sheep (Menard et al. 2005). Studies on human ESC 
immunogenicity have generated mixed results. Li et al. showed suppression of allogeneic 
mixed lymphocyte reactions (MLR) by 2-3 different human ESC lines in vitro, both 
before and after differentiation (Li et al. 2004). This immune suppression was totally 
mediated by cell-cell contact but not by soluble factors. However, when they transplanted 
the ESCs in vivo, they were able to show survival only up to 48 hours, although they 
found no leukocyte infiltration. Nevertheless, they claimed that ESCs possessed immuno-
privileged characteristics. Swijnenburg et al. also studied ESC immunogenicity by 
intramuscular xenotransplantation in a mouse model. Interestingly, they showed a longer 
survival of ESCs of 7 days, but reached a different conclusion (Swijnenburg et al. 2008). 
They were able to monitor the ESCs engraftment in real-time, using in vivo imaging 
system (Cao et al. 2006) detecting transgenically expressed luciferase signals. In their 
study, ESCs were often rejected after 1 week in immunocompetent mice, as opposed to 
teratoma formation in immuno-deficient mice. In contrast to Li’s findings (Li et al. 2004), 
they detected significant intragraft lymphocyte and macrophage infiltration and 
accelerated secondary rejection. They concluded that these observations indicated that 
ESCs trigger robust cellular and humoral immune responses. Grinnemo et al. had similar 
findings that grafted ESCs were heavily infiltrated and acutely rejected in 
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xenotransplantation (Grinnemo et al. 2006). In addition, in contrast to Li’s results, they 
found no immunosuppressive properties of ESCs in in vitro MLRs. Drukker et al. 
supported low immunogenicity of the ESCs in more comprehensive in vivo studies 
(Drukker et al. 2006). Their studies included a humanized mouse model reconstituted 
with human PBMCs. This was probably a more relevant system that helped defining 
possible allogeneic immune responses (Thomsen et al. 2005; Shultz et al. 2007) toward 
the ESCs. The transplanted ESCs developed into teratomas in this system, suggesting an 
escape from allogeneic rejection.  
In summary, general agreement has not been achieved about the immunogenicity 
of undifferentiated human ESCs. On the other hand, the immunogenicity studies of 
undifferentiated ESCs may not help evaluate the transplantability of their derivatives, 
which are more likely to be clinically useful than the undifferentiated ESCs.  
Current knowledge on the immunogenicity of differentiated ESCs is scarce. It has 
been shown in mice that ESCs derived hematopoietic progenitors could engraft 
allogeneic hosts and induce immune tolerance, after pre-conditioning with sublethal 
irradiation but without immunosuppression (Bonde et al. 2008; Verda et al. 2008). 
Robertson et al. reported rapid allorejection of mouse embryoid bodies which were a 
mixture of ESCs differentiated into various cell types at varying stages (Robertson et al. 
2007). Swijnenburg et al. found that mouse ESCs which had been differentiated into 
cardiomyocytes induced more potent and immediate allogeneic immune responses than 
their undifferentiated counterparts (Swijnenburg et al. 2005). For human ESCs, the 
immunogenicity of their differentiated derivatives may similarly vary depending on their 
specific cell types. According to Drukker’s study, MHC I expression in human ESCs 
increased during differentiation, both in vitro into embryoid bodies and in vivo into 
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teratomas (Drukker et al. 2002). In contrast, Draper et al. reported that MHC I expression 
in human ESCs was down-regulated during differentiation induced by retinoic acid, 
hexamethylene bisacetamide and dimethylsulphoxide (Draper et al. 2002). More work 
may be required to address this question because these differences in immunogenicity of 
ESCs may be related to many factors, including their source, their stage of differentiation, 
and the different cell types.  
 
2.2 Induced pluripotent stem cells  
Recently a whole new field of stem cell research has emerged, as the induced 
pluripotent stem cells (iPSCs). These are ESC-like cells induced by gene transfer into 
normal adult dermal fibroblasts. As ESC research advanced during the past decades and 
knowledge accumulating in development biology, many stem cell markers and specific 
transcription factors regulating differentiation have been identified. Thus, Yamanaka’s 
group (Okita et al. 2007) postulated that by re-expressing these genes in adult cells, it is 
possible to revert the cells back into early developmental stage. They were able to screen 
out the 4 key genes out of 24 candidates—Oct3/4, SOX2, Myc and KLF4. Their method 
with mouse cells was quickly applied to human cells and proved successful (Takahashi et 
al. 2007; Park et al. 2008). Then Myc was removed from the four necessary factors and 
the new protocol generated iPSCs with reduced tumorigenecity (Nakagawa et al. 2008). 
The iPSCs are generated completely independent of ESCs but resemble ESCs in most 
aspects. The iPSCs are morphologically and functionally equivalent to ESCs, expressing 
ESC markers, forming teratomas in immunodeficient hosts and contributing to cells types 
in chimeric animals. Comparative gene-expression profiling showed close correlations as 
well as differences between iPSCs and ESCs. On the whole, this technique provides a 
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possible ESC alternative without ethical issues and allo-transplant rejection. Since the 
source of iPSCs is supposed to be autologous, immune rejection is not yet a concern. And 
this is a significant advantage of iPSCs, regarding regenerative medicine. But given the 
cost and effort required in generating each iPS cell line, the clinical application of iPS 
cells may not be limited to only one patient, the donor of the cells. If another recipient is 
intended, the immunogenicity of the iPS cells and their derivatives would become 
important and require immunosuppression of the host response. 
In addition, some diseases, like type 1 diabetes, have a significant autoimmune 
component in the pathophysiology. The iPSCs, after successful differentiation into 
insulin secreting islet cells (which has not been achieved so far despite many attempts), 
may still be subjected to the same autoimmune process of destruction. 
However, before transplant engraftment and immune rejection become of concern, 
the clinical application of ESCs and iPSCs is still faced with serious regulatory issues. 
Teratoma formation is the key feature of their stemness but poses potential risk of 
iatrogenic oncogenesis.  
 
2.3 Bone marrow derived mesenchymal stem cells 
 Adult stem cells, also known as somatic stem cells, are found throughout body 
after embryonic development, in various tissues and organs. They are undifferentiated 
cells that multiply by cell division to replenish dying cells and regenerate damaged 
tissues. There have been many studies on adult stem cells, given the variety of their types. 
Based on the theme of the present study, one selected type of adult stem cells, the bone 
marrow mesenchymal stem cell, which has proven clinical utility and immunomodulatory 
properties, will be discussed and reviewed. 
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 Mesenchymal stem cells are adherent, fibroblastoid-like, multipotent cells which 
can differentiate into different cell types of the mesenchymal lineage, e.g. adipocytes, 
osteocytes, chondrocytes, etc. (Pittenger et al. 1999).  Recent studies suggest that MSCs 
may be able to transdifferentiate across germ layers, e.g. into hepatic (Lee et al. 2004; 
Sato et al. 2005) and neural (Kopen et al. 1999; Tatard et al. 2007) lineages. The MSCs 
are primarily isolated from the bone marrow, but also have been found in several other 
human adult tissues, including adipose tissue (Zuk et al. 2002), dental pulp 
(Pierdomenico et al. 2005) and synovium (De Bari et al. 2001). With the increasing 
diversity discovered for the MSC sources, researchers postulated that mesenchymal stem 
cells reside in connective tissues of most organs (da Silva Meirelles et al. 2006). But the 
lack of definitive markers does not allow simple identification and characterization of the 
MSCs. Among all the MSCs, the bone marrow derived mesenchymal stem cells (BM-
MSCs) are the best known. BM-MSCs reside in the bone marrow in close proximity to 
the hematopoietic stem cells (HSCs). They have been found to enhance the engraftment 
and to attenuate graft versus host disease in HSC transplantation (Le Blanc et al. 2004; Le 
Blanc et al. 2007). Recently, BM-MSCs have been reported to exert immunomodulatory 
functions, and this has opened new areas of potential clinical applications. Recent studies 
have focused on trying to uncover the mechanisms of BM-MSC immune modulation. 
To understand the interactions between the MSC and the immune system, 
researchers have employed various in vitro methods, approaching the question in a step-





2.3.1   MHC expression 
 The major histocompatibility complex (MHC) molecules are the key players in 
immune recognition and antigen presentation. The MHC expressions on MSCs are 
directly linked to its immungenicity. The lack of immunogenicity of MSCs has 
sometimes been attributed to their low expression of MHC class I and lack of MHC class 
II antigens (Le Blanc et al. 2003).   
Nonetheless, induction of MHC II surface expression has been reported when 
MSCs undergo IFN-γ stimulation (Romieu-Mourez et al. 2007).  This has raised concerns 
of MSCs acting as antigen presenting cells (APCs) in an inflammatory environment. 
Chan et al. suggested that MSCs possess APC-like functions in vitro (Chan et al. 2006). 
Their MHC class II expression could be maintained by the endogeneous low level of 
IFN-γ expression and were compromised by high dose IFN-γ added to the culture 
medium (Tang et al. 2008).  Thus it was concluded that the APC function of MSCs 
occurred only in a narrow window and the immunosuppressive function would be 
switched on as inflammation progressed. This has been supported by more recent studies 
by Krampera M et al. (Krampera et al. 2006) and Chan et al. (Chan et al. 2008).  
 
2.3.2 T lymphocytes 
 T lymphocytes play a central role in cell-mediated immunity. Clonal expansion of 
the T cells is one of the important steps during the initiation of an adaptive immune 
response. Hence the inhibition of T cell proliferation is a crucial step of preventing 
subsequent immune activation and attack. It has been generally accepted that MSCs 
inhibit T cell proliferation triggered either by allogeneic, mitogenic or antigen-specific 
stimuli (Di Nicola et al. 2002; Krampera et al. 2003; Aggarwal et al. 2005). Both CD4+ 
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and CD8+ T cells have been shown to be susceptible to MSC inhibition (Krampera et al. 
2006). The inhibition of cytotoxic T cells (CTLs) proliferation by MSCs has been 
suggested to account for the inhibition of cytotoxic effects of these cells (Rasmusson et al. 
2003).  
To understand how MSCs inhibit T cell proliferation, several possible 
mechanisms have been proposed and examined, such as induction of T cell anergy or 
apoptosis, and induction of regulatory T cells phenotype. T-cell anergy has been 
proposed as a potential mechanism of MSC immune modulation, based on the 
observation that MSCs lack surface expression of costimulatory molecules 
(Klyushnenkova et al. 2005). This has been supported by both in vitro and in vivo studies 
showing that MSCs induced an unresponsiveness of T cell, possibly via cell division 
arrest (Glennie et al. 2005; Zappia et al. 2005; Batten et al. 2006). Plumas et al. reported 
that MSCs inhibited T-cell proliferation by inducing apoptosis of activated T cells, while 
having no effect on resting T cells (Plumas et al. 2005). MSCs have been reported to 
induce the expansion of CD4+CD25+ T cells which expressed Foxp3, which were thought 
to be a regulatory T cell phenotype (Batten et al. 2006; Selmani et al. 2008). Furthermore, 
Prevosto et al. demonstrated that these cells functionally suppress T cell proliferation, and 
this regulatory functionality was not limited to CD4+ cells but was also observed in CD8+ 
T cells treated with MSCs (Prevosto et al. 2007).  
Researchers have also attempted to identify molecules via which MSCs exerted 
an inhibitory effect on T cell proliferation. Indoleamine 2,3-dioxygenase (IDO), an 
enzyme that degrades the essential amino acid tryptophan, has been shown to have a role 
in MSC mediated T cell inhibition (Meisel et al. 2004), as addition of either IDO 
inhibitors or tryptophan could restore T cell proliferation. However, Sato et al. did not 
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observe this restoration effect using IDO inhibitor in a similar study. Instead, they 
proposed the involvement of nitric oxide, suggesting that it was produced by MSCs in 
response to T cells and it might be involved in the suppression of Stat5 phosphorylation 
in T cells with a consequent reduction in T cell proliferation (Sato et al. 2007). Another 
candidate molecule was prostaglandin E2, as inhibitors of prostaglandin synthase have 
also been shown to mitigate MSC-mediated inhibition of T cell proliferation (Aggarwal 
et al. 2005; Sato et al. 2007).   
A recent study investigated the role of HLA-G, a non-classical MHC class I 
molecule known for immunosuppressive functions during pregancy, in the MSCs 
immune modulation scenario (Nasef et al. 2007). The function of HLA-G was 
demonstrated and verified using a blocking antibody. However, it is uncertain how 
difficult it will be to generate an HLA-G positive and stable MSC population, since its 
expression is only found in a subpopulation of MSCs and has been shown in one study to 
decrease over passages (Selmani et al. 2008).  
 
2.3.3 Dendritic cells 
 As a major antigen presenting cell, the dendritic cell (DC) plays the important role 
of linking innate immunity to adaptive immunity, without which the education and 
activation of T cells cannot be facilitated. Rather than interfering with dendritic cell 
function directly, MSCs have been reported to impair the differentiation and maturation 
of DCs, resulting in poorly functional DCs (Jiang et al. 2005).  Not only did MSCs block 
initial commitment and differentiation of monocytes into DCs, resulting in both 
morphological and phenotypical defects and loss of function in lymphocyte stimulation, 
but MSCs also modulated cytokine secretion when introduced into mature DC cultures.  
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Interestingly, this effect was shown to be independent of direct cell-cell contact, and has 
been observed with DCs from different progenitors (Nauta et al. 2006; Chen et al. 2007).  
The interactions between MSCs and DCs are still under investigation. One recent 
study by Ramasamy’s group (Ramasamy et al. 2007) suggested that MSCs may block DC 
differentiation by arresting monocytes in the G0 phase of the cell cycle. Spaggiari et al. 
suggested that prostaglandin E2 might be the key mediator in the MSC inhibition of DC 
maturation (Spaggiari et al. 2009). This was supported by a similar study reported by 
Chen et al. (Chen et al. 2007).  
 
2.3.4 B lymphocytes and natural killer cells 
 These are the less studied immune cells in the MSC immune modulation model.  
B cells are mainly involved in humoral immunity and take action indirectly and more 
slowly. Currently the very limited information on this topic from the few studies has 
turned out to be controversial. MSCs have been reported to either have no effect on 
(Meisel et al. 2004) or to suppress B cell proliferation (Corcione et al. 2006). Different 
studies have also reported differing effects of MSCs on B cell antibody production, as 
stimulatory (Rasmusson et al. 2007) versus inhibitory (Corcione et al. 2006). More 
studies on MSC effects and interaction with B cell function would be necessary for our 
understanding.  
Interactions between natural killer (NK) cells and MSCs are important in the field 
of transplantation, as these cells are the key mediators of innate immunity. It has been 
reported that activated NK cells were able to lyse MSCs (Spaggiari et al. 2006).  
However, the story is a complicated one—several studies have consistently shown strong 
 20
inhibition of NK proliferation by MSCs (Meisel et al. 2004; Sotiropoulou et al. 2006; 
Spaggiari et al. 2008).   
In summary, human mesenchymal stem cells employ complicated mechanisms in 
carrying out modulation of the immune response. MSCs possess a broad range of 
immunosuppressive properties, inhibiting the proliferation of T cells and NK cells and 
inhibiting the development of dendritic cells. These functions are under control of 
multiple factors including cytokines, metabolical enzymes. All in all, MSCs may 
eventually be very important in clinical applications, either for stem transplantation or for 
supportive immune modulation during other types of therapies. The current challenges 
still lie with the understanding of the underlying mechanisms and the characterization of 
definitive MSC markers.  
 
2.4 Fetal/neonatal stem cells 
2.4.1 Background 
 Fetal and neonatal stem cells come in between embryonic and adult stem cells in 
the developmental continuum. Studies of these cells have provided information and 
insights into the biology of stem cells in general. These cells have also been considered 
for therapeutic applications, as alternative cell sources to embryonic and adult stem cells, 
with some unique and fascinating features.  
Neonatal stem cells can be isolated from the extraembryonic tissues, which are 
normally discarded once the baby is delivered, and thus have fewer ethical issues. In 
addition, procurement is relatively easy, and would not involve invasive procedures to the 
donor since the placenta and umbilical cord are part of the delivery. On the other hand, 
the source of fetal cells is primarily from abortions, and use of fetal stem cells has been 
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the subject of some ethical debate. In this review, discussion of fetal stem cells will be 
limited to amniotic fluid stem cells, which can be obtained through amniocentesis, a 
widely accepted, minimally invasive form of prenatal disgnostic testing.  
As juvenescent cell sources, fetal and neonatal stem cells may be relatively free of 
mutations that can accumulate over the lifetime of an organism. They may also possess 
greater proliferative potential and plasticity than adult stem cells. Although all stem cells 
are self-renewing and multipotent by definition, differences exist between stem cells from 
young and aged donors (Roobrouck et al. 2008). This has been best studied in 
hemapoietic stem cells, for which researchers have shown both quantitative and 
qualitative changes during the aging process (Vaziri et al. 1994; Chambers et al. 2007). 
Similarly, ontogeny related changes have also been found in bone marrow derived MSCs, 
resulting in decrease of both the frequency and expansion capacity of the MSC 
population (Stolzing et al. 2008; Zhou et al. 2008b). 
In addition, fetal/neonatal stem cells may potentially possess immunomodulatory 
properties associated with the fetal/maternal interface, which has been known as an 
immuno-privileged site. Studies of fetal/neonatal stem cells are being performed to 
further our understanding of the immune modulation during pregnancy and to investigate 
their potential use in autoimmune diseases or in cell transplantation. This will be 
reviewed in greater detail in the following sections. 
 
2.4.1.1 Immune tolerance in pregnancy 
 Immune tolerance is necessary and crucial during pregnancy because the fetus 
with half of the genes from the father is a semi-allograft to the mother. For the mother’s 
immune system to avoid attacking the fetus, processes of immune tolerance or immune 
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suppression may be required. The mechanisms of how this happens have not been fully 
understood yet. Other processes in pregnancy are also equally complex, e.g. successful 
placentation is unlikely to be dependent on a single factor, but would probably be the 
result of complex interactions between fetal antigenicity and specific maternal 
immunoreactivity.  
 Uterine natural killer cells (uNK) and extravillous trophoblasts (EVT) may be two 
of the important cell types involved in immune tolerance during pregnancy. The uNK 
cells are members of the maternal immune system. The EVTs are derived from the 
trophectoderm of the embryo and invade into the decidualised uterus during placentation. 
These two types of cells have direct contact and active interactions at the interface 
between the mother and the fetus.    
Since there is close contact between the EVTs and uNK cells, immune regulation 
is required to protect the EVT from NK cytotoxicity. Studies have indicated that 
hormonal and cytokine environment have a significant impact (Saito 2000). Besides that, 
immune recognition through direct ligand/receptor interactions between the EVT and 
uNK cells is also important. The classical HLA-A, B molecules, which are ubiquitously 
expressed in almost all nucleated cells, are down-regulated in EVT (Carosella et al. 2008). 
The lack of HLA-A, B and MHC II molecules makes the EVT unrecognizable by 
maternal T cells but at the same time makes them vulnerable to NK cells cytotoxicity. 
The EVT still expresses HLA-Cs, which are ligands to the killer cell immunoglobulin-
like receptors (KIR). The interactions between HLA-C and the KIR can be either 
inhibitory or activating, given the high polymorphism of both genes, thus tightly regulate 
EVT and uNK cells in the remodeling of spiral arteries for the fetal blood supply (Parham 
2004).  
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A novel HLA antigen was discovered in EVTs in 1986 (Ellis et al. 1986), not 
being masked by the otherwise ubiquitously expressed and abundant HLA-A, B class Ia 
molecules. This nonclassical MHC-Ib antigen, later known as HLA-G, was thought to 
have a specific tissue distribution in the EVTs, which indicated specific functions in the 
modulation of immune tolerance during pregnancy.  
 
2.4.1.2 HLA-G in immune tolerance 
 The HLA-G gene is a member of the HLA class I genes, which include the 
classical HLA-A, B, C, the non-classical HLA-E, F, G and a few pseudogenes. Although 
MHC genes are generally known for their astounding allelic diversity, HLA-G has only 
44 alleles known so far. Many of these polymorphisms are synonymous or affect non-
coding regions and only 14 protein variants have been assigned. This is in contrast to the 
classical HLA-A, B, C which have 853, 1249, and 463 alleles respectively, crowning the 
most conspicuously diverse loci in the human genome (IMGT/HLA database). Their high 
polymorphism allows the widest possible range of foreign peptides being presented. On 
the other hand, functions of the non-classical members HLA-E, G, F are not fully 
understood as yet.  
 
2.4.1.2.1 HLA-G receptors 
 HLA-G is structurally similar to MHC-Ia antigens and binds to CD8. However, 
based on its very low polymorphism, very limited tissue distribution and slow turnover at 
the cell surface, it has been suggested that antigen presentation is unlikely to be the 
primary function of HLA-G (Le Bouteiller et al. 2001). 
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The HLA-G functional pathways largely remain to be explored. Up to date, four 
HLA-G receptors/ligands have been identified—ITL2, ILT4, KIR2DL4/p49 and CD8. 
ILT2, 4 (LIR1, 2) are two inhibitory receptors from the immunoglobulin-like transcript 
(also called leukocyte immunoglobulin-like receptor) family. ILT2 is broadly expressed 
on both the lymphoid and myeloid cells. ILT4 is expressed mainly by myeloid cells and 
also has been detected at low levels in NK cells (Borges et al. 1997). ILT2 and ITL4 bind 
to a broad range of MHC antigens, but their affinity to HLA-G is three to four times 
higher than to the classical MHC-Ia molecules (Shiroishi et al. 2003). Naji et al. provided 
evidence that HLA-G functions through ILT2, ILT4 and Fas ligand, with Fas ligand 
probably in the downstream signaling pathway (Naji et al. 2007a). The killer-cell 
immunoglobulin-like receptor KIR2DL4/p49 is an NK cell inhibitory receptor 
(Rajagopalan et al. 1999). Interestingly, there are indications that HLA-G may be able to 
upregulate the ILT2/4 and KIR2DL4/p49 receptors expression in APCs, NKs and T cells, 
thus sensitizing the immune cells for its action (LeMaoult et al. 2005). 
 
2.4.1.2.2 HLA-G functions 
Many in vitro studies have been carried out by different research groups to 
demonstrate and dissect the immunosuppressive functions of HLA-G, using purified 
immune cell preparations. As mentioned earlier, the HLA-G receptors are expressed by a 
variety of immune cells. As a result, HLA-G interacts with and has impact on multiple 
immune cell types, including NK cells, T and B lymphocytes and APCs.  
For NK cells, HLA-G has been shown to inhibit the proliferation and cytotoxic 
function of both uterine and peripheral blood NK cells (Rouas-Freiss et al. 1997). This 
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provides direct evidence to support the role of HLA-G in protecting the semi-allogeneic 
fetal cells from uNK cytolysis at the maternal/fetal interface (Rouas-Freiss et al. 1997).  
HLA-G has been shown to inhibit the proliferation of both CD4+ and CD8+ T 
cells (Bahri et al. 2006). It also inhibits the alloreactivity of CD4+ T cells (Riteau et al. 
1999) and the cytotoxicity of CD8+ T cells (Le Gal et al. 1999). It has also been reported 
that HLA-G induces CD8+ apoptosis via the Fas signaling pathway (Fournel et al. 2000).  
Additionally, HLA-G has been implicated in the generation of regulatory T cells. 
This is important because regulatory T cells play key roles in maintaining immune 
system homeostasis and mediating immune tolerance. A group from France has done a 
series of studies to show that both the membrane and soluble isoforms of HLA-G are able 
to induce an immunosuppressive phenotype in T cells (LeMaoult et al. 2004; Le Rond et 
al. 2006). They subsequently have characterized these regulatory T cells as CD3+CD4low 
and CD3+CD8low and Foxp3 negative (Naji et al. 2007). They have reported that the 
generation of these cells was dependent on IL-10, but further study will be required to 
determine whether these are Type 1 regulatory T cells. However, to date, all these 
observations have not yet been reproduced by other groups working on HLA-G. 
HLA-G may also affect T cell function indirectly through APCs. One group from 
Georgia did a series of studies and suggested that HLA-G induces the development of 
tolerogenic DC, which in turn induces differentiation of anergic and immunosuppressive 
effector T cells (Ristich et al. 2005; Smith et al. 2008). In one of these studies, Ristich et 
al. reported that HLA-G inhibited the maturation and function of DCs, but no such effect 
was observed with soluble HLA-G in another study by Le Friec et al. (Le Friec et al. 
2003). The different results might be explained by different HLA-G molecules that the 
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two groups used. Ristick et al. treated the DCs with HLA-G1 tetrameric complexes, while 
Le Friec et al. used recombinantly expressed soluble HLA-G.  
The above two reports illustrate one of the problems with HLA-G studies: the 
different sources and molecular forms of the HLA-G molecules used in the different 
studies have sometimes made it difficult to compare and interpret the results.  
This is mainly due to alternative splicing patterns of HLA-G mRNA, generating 
seven different protein isoforms. These include four membrane-bound (HLA-G1 to -G4) 
and three soluble isoforms (HLA-G5 to -G7). In addition, a soluble HLA-G1 isoform is 
thought to be generated by proteolytic cleavage of the membrane HLA-G1 (shed HLA-
G1). The main isoforms studied so far are the full length HLA-G1, shed HLA-G1 and 
HLA-G5. Much less is known about the other isoforms.  
To date, the functions of HLA-G1 and G5 are thought to be similar but proper 
comparative studies are lacking. It is possible that HLA-G isoforms are involved in the 
regulation of its expression and function, in which case each isoform would need to be 
distinguished carefully.  
Besides the isoforms, protein oligomerization may also be important in its 
regulation. The different molecular forms of HLA-G used in each experimental setting 
could have direct impact on the outcome. HLA-G has been detected at the surface of 
normal human trophoblast as a disulphide-linked homodimer of the conventional β2-
microglobulin-associated HLA-I complex (Apps et al. 2007). This study has also shown 
that the dimerized HLA-G complex has an increased affinity with its receptor ILT2 
compared to the conventional HLA-G-β2-microglobulin complex. Future studies may 
have to take this into consideration.  
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The use of recombinant HLA-G proteins in functional studies may not cause a 
problem if the complexes are correctly constructed. However, there is an additional 
problem of using HLA-G cDNA transfected cell lines as a model for membrane bound 
HLA-G isoforms. Most of the studies reviewed above have employed 
transformed/immortalized cell lines, which do not express HLA-G endogenously. 
Although those experiments were all carefully controlled to exclude effects by factors 
other than HLA-G, the specific cell type and its other surface markers might have an 
impact on the HLA-G functions on the target cells. Hence, a primary cell type with 
endogenous HLA-G expression and physiological regulatory machineries would be 
valuable for the studies of HLA-G functions.  
 
2.4.1.2.3 In vivo evidence of HLA-G function 
Besides expression in the trophoblasts at the maternal/fetal interface, HLA-G has 
been detected in vivo in a few other scenarios, all of which add on as supportive evidence 
to its role in immune modulation. Soluble HLA-G levels in maternal serum have been 
shown to be predictive for a successful pregnancy, as low HLA-G serum levels have been 
associated with pre-eclampsia, one of the most common pregnancy complications 
(Athanassakis et al. 1999; Yie et al. 2005).  
The immunosuppressive properties of HLA-G in vivo have also been suggested in 
the escape of tumors from immune surveillance where its expression is upregulated 
specifically in some tumor cells (Ibrahim et al. 2001; Yie et al. 2007). HLA-G has also 
been implicated in autoimmune diseases with lower serum levels of soluble HLA-G 
associated with susceptibility to systemic lupus erythematosus (Rizzo et al. 2008).  
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Furthermore, HLA-G has been reported to positively correlate with better graft 
acceptance and reduced rejection in allo-transplantations, including hematopoietic stem 
cells, kidney, heart and combined liver/kidney transplantations. Significant positive 
correlations have been shown with both the soluble HLA-G serum level (Qiu et al. 2006; 
Crispim et al. 2008; Le Maux et al. 2008) and its local expression (Lila et al. 2002; 
Creput et al. 2003). In heart transplant patients, myocardial HLA-G expression has been 
negatively associated with acute cellular rejection and cardiac allograft vasculopathy 
(Sheshgiri et al. 2008b). Based on these results, HLA-G has been suggested as a 
prognostic indicator of graft tolerance. A search for future therapeutic agents that can be 
targeted toward inducing HLA-G expression has just begun (Sheshgiri et al. 2008a).  
Based on these findings, it is foreseeable that a transplantable cell line that 
naturally expresses HLA-G may be potentially very valuable for therapeutic applications.  
 
2.4.1.3 HLA-E   
HLA-E is another member of the MHC-Ib antigen family. HLA-E is more 
ubiquitously expressed but its surface expression depends on the leader peptides of other 
MHC I molecules including HLA-G (Lee et al. 1998a). HLA-E binds to another NK cell 
inhibitor CD94/NKG2A (Lee et al. 1998b) and it may play an immunomodulatory role 
supplementary to HLA-G. 
 
2.4.1.4 Pregnancy related tissues in cell therapy   
In view of the above, pregnancy related tissues have been studied for their 
potential in cell therapy in the hope of the extra advantage of immunosuppressive 
properties. Extraembryonic tissues, especially the placenta, which forms an anatomical 
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barrier between the mother and fetus, have been thought to play important roles in the 
modulation of immune tolerance during pregnancy. Cell transplantation with either 
amnion or chorion cells into neonatal animals resulted in chimerism in various tissues 
and organs (Bailo et al. 2004). An in vivo study using amniotic membrane also showed 
none to mild immune cell infiltration and significantly better acceptance by the host than 
normal skin grafts (Kubo et al. 2001). Attempts have been made to isolate and 
characterize stem cells from these tissues. Some preliminary studies have investigated the 
immunological properties of these cells. These studies will be reviewed in detail in the 
following sections.  
 
2.4.2 Amniotic fluid stem cells 
 The amiotic fluid is the nourishing and protecting liquid surrounded by the 
amnion of a pregnant woman. In early gestation, the amnion grows and begins to fill with 
mainly water, which moves passively down the chemical potential gradient from the 
maternal circulation, accompanying active transport of solutes across the amniotic 
membrane and fetal skin. In the later half of gestation, the amniotic fluid comes mostly 
from fetal urine, and also from lung secretions. The fluid dynamics is partly balanced by 
resorption through fetal swallowing (Beall et al. 2007). As a result, cells present in the 
urogenital, respiratory and gastrointenstinal tracts, as well as the amniotic membrane and 
the fetal skin, can be shed into the amniotic fluid. As early as in 1974, Hoehn et al. 
classified the viable adherent cells from amniotic fluid into three major groups: 
epithelioid (E-type), amniotic fluid (AF-type) and fibroblastic (F-type) cells (Hoehn et al. 
1974). E-type cells have been thought to derive from fetal skin and urine, AF-type cells 
from fetal membranes and trophoblasts and F-type cells from fibrous connective tissue 
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and dermal fibroblasts. Bossolasco et al. also described very heterogenous sizes and 
morphologies in the amniotic fluid derived cells, including small epithelium-like cells, 
larger cells with irregular and swelling borders, sometime bi-nucleated or with a high 
nuclear cytoplasmic ratio, and fibroblastic cells (Bossolasco et al. 2006). This mixture of 
cells in the amniotic fluid is termed amniocytes. Although these cells (and other 
components/properties of the fluid) have been used for prenatal diagnosis for a wide 
range of fetal abnormalities, their specific origins largely remain to be determined 
(Gosden 1983). Despite their heterogeneous nature, amniocytes represent an accessible 
source of fetal cells. The possibility of using amniotic fluid as a source of multipotent 
stem cells has been explored in the past decade or so.  
The earliest literature about progenitor cells found in the amniotic fluid dates back 
to 1993. Torricelli et al. (Torricelli et al. 1993) reported the presence of hematopoietic 
progenitor cells taken before the 12th week of gestation but not later. They suggested that 
these cells may come from the yolk sac and they observed significant changes in 
amniocyte composition during gestation. Their findings did not indicate any potential of 
amniotic fluid as a source for hematopoietic progenitor cells.  
Some researchers tried to identify stem cells in the amniotic fluid using known 
stem cell markers. Oct-4 is an important stem cell transcription factor which is required 
to maintain pluripotency. Prusa et al. were able to demonstrate nuclear expression of Oct-
4 in ~0.1–0.5% of amniotic fluid cells, which concomitantly express cyclin-A indicating 
active cell division (Prusa et al. 2003). They also detected mRNA of vimentin, stem cell 
factor and alkaline phosphatase which correlated with Oct-4 expression. However, nearly 
half their samples (6 out of 11) were negative for Oct-4. These stem cells therefore 
represent a very rare and heterogeneous population in the amniocytes, their purification 
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will require much effort (Karlmark et al. 2005) and their differentiation potential is yet to 
be validated. 
De Coppi et al. defined a population of pluripotent amiotic fluid stem cells 
(AFSCs) through selection of c-kit, the receptor for stem cell factor (De Coppi et al. 
2007a). The c-kit+ AFSCs could be differentiated into adipogenic, osteogenic, 
chondrogenic (Kolambkar et al. 2007), myogenic, endothelial, neuronal, hepatic and 
renal (Perin et al. 2007) lineages, inclusive of all 3 germ layers. No spontaneous 
differentiation or tumor formation in immuno-deficient mice was observed in the 4 AFSC 
lines tested. Although scarce in number, the AFSCs continue to be studied, as they have a 
high renewal capacity and can be expanded for over 250 doublings without any 
detectable loss of chromosomal telomere length (De Coppi et al. 2007). As a further step 
towards clinical application, the AFSCs have been transplanted into animal models and 
evaluated in vivo. Successful engraftment and differentiation have been observed in 
neonatal injected twitcher mouse model for neurogenic differentiation, in 
immunodeficient mice for tissue engineered bone formation, in microinjected mice 
embryonic kidney for contribution to the development of primordial kidney structures 
(Perin et al. 2007), and in cultured murine embryonic lung for differentiation into lung 
epithelial lineages (Carraro et al. 2008). However, attempts to induce dopamine neuron 
and cardiomyocyte differentiation using these AFSCs in vitro and in vivo have not been 
successful (Chiavegato et al. 2007; Donaldson et al. 2009) . 
Besides the Oct-4 or c-kit selected stem cells, many researchers have looked at the 
amniotic fluid as an source of mesenchymal stem cells (In’t Anker et al. 2003). In view of 
the low frequency of MSCs present in the bone marrow (0.001-0.01% nucleated cells), 
researchers have been investigating alternative sources of MSCs. The isolation of 
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amniotic fluid MSC (AF-MSC) has been reported using its property of adherence to 
plastic culture plates containing MSC culture medium. In the AF-MSC studies to date, 
consistently high success rates of MSC isolation from the second trimester have been 
reported. The frequency of AF-MSCs in the amniotic fluid samples have been estimated 
to range from 0.9%-1.5% (Roubelakis et al. 2007). These cells are phenotypically 
(morphology and markers expression) and functionally (multipotency and immune 
modulation) similar to bone marrow derived MSCs (In’t Anker et al. 2004; Tsai et al. 
2004; Roubelakis et al. 2007; Sessarego et al. 2008). The AF-MSCs have been tested in 
osteogenic, adiogenic, neurogenic and hepatogenic differentiation protocols successfully 
(Roubelakis et al. 2007). Independent research groups have shown that AF-MSCs have 
significantly greater potential of culture expansion than BM-MSCs (Roubelakis et al. 
2007; Sessarego et al. 2008). This is consistent with Sessarego et al.’s finding that AF-
MSCs have longer telomeres than BM-MSCs (Sessarego et al. 2008). This superior 
proliferative property of AF-MSC is supported by Iop et al.’s in vivo comparative studies 
with rat AF-MSCs and BM-MSCs (Iop et al. 2008). Moreover, all of the above literature 
about AF-MSCs have reported nontumorigenecity and karyotype stability.  
Despite the advantages described, in vivo studies of the AF-MSCs are still limited. 
De Coppi et al. reported similar results of poor engraftment and differentiation of both 
AF-MSCs and BM-MSCs in a syngeneic cryo-injured rat bladder transplantation model, 
although both types of MSCs did have an effect of regulating post-injury bladder 
remodelling (De Coppi et al. 2007). Iop et al. also compared AF-MSC and BM-MSC in 
sygeneic transplantation into a rat model of heart cryo-injury (Iop et al. 2008). Although 
in the intial engraftment AF-MSCs had only half the survival compared to BM-MSCs at 
day one, they proliferated more actively subsequently and had similar numbers of 
 33
surviving cells compared with BM-MSCs on day 30 post-transplantation. The AF-MSCs 
did not give rise to as many smooth muscle cells as the BM-MSCs, which led to fewer 
arterioles and capillaries. They nonetheless were able to differentiate in vivo into 
endothelial cells and cardiomyocytes and were able to reconstitute the injured 
myocardium. 
An important deficiency in the understanding of amniotic fluid stem cells has 
been the lack of studies on their immunogenicity. An in vitro immunological study 
reported that AF-MSCs inhibited both anti-CD3/anti-CD28 and PHA stimulated T cell 
proliferation in a dose-dependent manner (Sessarego et al. 2008). A few in vivo studies 
used xenotransplantations of human AF stem cells into animal models. These were done 
with immunosuppression and had variable outcomes in terms of graft survival. 
Donaldson et al. transplanted human c-kit+ selected AFSCs into rat brains of a Parkinsons 
disease model and reported acute rejection (Donaldson et al. 2009). In contrast, Cipriani 
et al. observed up to 90 days surivial of AF-MSCs in the ischemic rat brain (Cipriani et al. 
2007). Both studies used cyclosporin for immnuosuppression. This difference in survival 
has not been explained so far and may be attributed to differences in the experimental 
settings.  
The origin of AFSCs is still largely unclear. As discussed earlier, this has been an 
intrinsic problem with the amniotic fluid extracted cells. Selection of cells using a single 
marker may not guarantee a homogeneous cell population, as the amniocytes could 
readily be shed from various embryonic/extraembryonic/fetal compartments or even 
maternal tissues, at different developmental stages during the gestation. HLA-typing of 
the AF-MSCs have shown instances of fetal/maternal cell mixtures, and it may depend on 
the route of amniocentesis (In’t Anker et al. 2004).  
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2.4.3 Placental stem cells 
 The human placenta is a large fetomaternal organ which plays a fundamental and 
essential role in fetal development, nutrition, and tolerance. The full-term placenta is a 
neonatal tissue, disposed after birth, with a size of around 50 cm2 and a weight of about 
500g. Placental tissue has been used in clinical treatments for over 100 years. Its 
application has included fields of ophthalmology, surgery and wound healing. Stem cell 
researchers have begun to explore placental tissue as a source of stem cells in the past 
few years.  
The placenta is a complex organ. Four regions of fetal origin can be distinguished 
from which different cells can be isolated: amniotic epithelial, amniotic mesenchymal, 
chorionic mesenchymal and chorionic trophoblastic. Embryologically, the amnion is 
derived from the embryonic epiblast, whereas the chorion is extraembryonic and 
trophoblastic in origin. Hence, the search of placental stem cells has focused more on the 
amnion membrane. This is also because of anatomical location of the chorion which leads 
to higher chance of maternal contamination.  
The amniotic membrane, or the amnion, consists of three layers: an inner 
monolayer of epithelial cells, an intermediate basement membrane lacking any cellular 
component and an outer mesenchyme layer juxtaposed to the chorion. From different 
layers of the amnion, pluripotent cells have been derived as amniotic epithelial cells 
(AECs) from the amniotic epithelium, and the amniotic mesenchymal cells (AMCs) from 





2.4.3.1 Amniotic epithelial cells 
 Research with amniotic cells has focused more on the epithelial cells than on the 
mesenchymal cells. Histological studies with tissue sections have shown that the amniotic 
epithelium but not the mesenchymal layer stained positive for a series of stem cell 
markers including SSEA-4, TRA 1-60 and TRA 1-81 (Miki et al. 2007). These markers 
have been detected in isolated and cultured hAECs. In addition, mRNA expressions of 
Oct-4, Nanog, SOX2, REX1 and telomerase reverse transcriptase (TERT) have also been 
detected in these cells (Miki et al. 2005). 
 In addition of stem cell marker expression, hAECs have been reported to possess 
other stem cell characteristics. These cells readily attached to plastic or basement 
membrane-coated culture dishes, and displayed typical cuboidal epithelial morphology. 
The AECs proliferated robustly in culture in the presence of epidermal growth factor 
(EGF) and formed spheroid structures. Miki et al. further showed in vitro differentiation 
of human AECs into pancreatic, neural, cardiac and hepatic lineages, with the induction 
of respective lineage-specific markers (Miki et al. 2005). Ilancheran’s group similarly 
reported differentiation of hAECs toward multiple cell lineages including cardiomyocytic, 
myocytic, osteocytic, pancreatic etc. with varying degrees of success (Ilancheran et al. 
2007). The suggestion that hAECs may be pluripotent was further supported by 
Tamagawa et al.’s report that xenogeneic chimeras could be formed with human AECs 
and mouse ESCs in vitro (Tamagawa et al. 2004). The hAECs contributed to all three 
germ layers.  
Given these stem cell characteristics of the hAECs, they have been tested as a 
source for cell replacement therapy and ex vivo gene therapy. Human AECs survived for 
3 weeks in the rat brain of a Parkinsons disease model and prevented degeneration of 
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dopaminergic neurons (Kakishita et al. 2003). Kosuga et al. showed that human AECs 
could be effectively transfected with adenovirus to overexpress a therapeutic transgene 
and improved CNS lesions in a mice model of lysosomal storage disorder (Kosuga et al. 
2001). Sakuragawa et al. have reported that hAECs could potentially be used as transgene 
carriers for cell transplantation into the liver (Sakuragawa et al. 2000), since they possess 
hepatocyte-like characteristics (Takashima et al. 2004) and can be genetically modified. 
Last but not least, Wei et al. reported correction of hyperglycemia in type 1 diabetic mice 
using human AECs after pancreatic differentiation, but this was not achieved with AMCs 
(Wei et al. 2003).  
 The above in vivo results are encouraging but they were carried out with immuno-
suppressed or immuno-deficient animals. A few transplantation studies with fully 
immunocompetent recipients have also been reported.  
As early as in 1981, Akle CA et al. transplanted allogeneic human amniotic 
epithelial membranes subcutaneously into seven human volunteers (before the existence 
of ethics committees), and reported the absence of acute rejection, and detected donor 
cells from biopsies for up to 7 weeks after transplantation (Akle et al. 1981).  
Xenotransplantation of hAECs into transected spinal cord of monkeys has been 
reported and human cells have been detected after as long as 60 days (Sankar et al. 2003). 
The animals were immunocompetent and did not receive any immunosuppressant drugs. 
Leukocyte infiltration was absent in both the transplanted and control animals, indicating 
a lack of immunogenicity of the hAECs. However, this was a pilot study with very small 
sample size (two animals in each group) and unknown cell numbers in the initial 
transplantation. Additionally, the spinal cord, being part of the CNS, might have limited 
immune responses, thus it might not be the best site for immunogenicity studies.  
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 In a recent study with a liver fibrosis model, hAECs have been detected in the 
liver after two weeks of intravenous injection into immunocompetent C57/BL6 mice 
(Manuelpillai et al. 2010). These transplanted hAECs expressed HLA-G and no signs of 
immune rejection were observed. The hAECs treatment led to decreased liver 
inflammation and fibrosis, with concomitant modulation of hepatic tissue cytokine 
concentrations. There has been another report also indicating the hAECs express mRNA 
and protein of HLA-G (Hammer et al. 1997). Further studies are required to investigate 
the isoforms expressed and their functions. 
These studies have consistently suggested that hAECs possess privileged 
immunogenicity, ability to modulate immune response and thus potentially favored 
transplantability. This may partly be attributed to the lack of alloantigen presentation. 
According to Ilancheran et al., naïve hAECs express very low levels of HLA-A, B, C and 
negligible levels of HLA-DP, DQ, DR (Ilancheran et al. 2007). In another study by Li et 
al., culture supernatants of hAECs significantly inhibited the chemotactic activity of 
neutrophils and macrophages toward macrophage inflammatory protein (MIP)-2 (Li et al. 
2005). They also reported that hAECs significantly reduced the proliferation of both T 
and B cells after mitogenic stimulation, partly by inducing lymphocyte apoptosis with the 
expression of Fas ligand. These effects were suggested to be mediated by soluble factors 
secreted by hAECs, which might include anti-inflammatory cytokines such as TGF-β and 
macrophage migration-inhibitory factor (MIF) (Li et al. 2005).  
 
2.4.3.2 Amniotic mesenchymal cells 
Amniotic mesenchymal cells have been isolated from the amniotic membrane, 
with a lower yield than hAECs (Soncini et al. 2007; Bilic et al. 2008). The two types of 
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amniotic cells can be distinguished by CD49d (α4-integrin), which has been shown to be 
expressed in hAMCs but not hAECs (Wolbank et al. 2007). It has been consistently 
reported that hAMCs express Oct-4 and a set of mesenchymal markers that are similar to 
bone marrow derived MSCs and lack expression of HSC markers. One comparative study 
has shown that both hAMCs and hAECs express embryonic stem cell markers SSEA-3 
and SSEA-4, but expression was weaker in hAMCs than in hAECs (Bilic et al. 2008). 
However, results from this study contradicted previous reports (Miki et al. 2005) in that 
slow proliferation was observed with both cell types and no TERT expression could be 
detected. This is probably due to the different isolation techniques and culture conditions 
used in different laboratories.  
Multipotency of hAMCs has been indicated in several preliminary studies, with 
the hAMCs undergoing adipogenic, osteogenic, chondrogenic, myogenic, 
cardiomyogenic and neuroglial differentiation in vitro (Sakuragawa et al. 2004; Soncini 
et al. 2007; Wolbank et al. 2007; Tsuji et al. 2010). Spontaneous differentiation into 
endothelial cells has also been shown when hAMCs were cultured in a matrigel system, 
indicating angiogenic potential (Alviano et al. 2007).  
Immunophenotyping of hAMCs has shown expression of MHC-I but lack of 
expression of MHC-II antigens. A dose-dependent immunodulatory effect of hAMCs has 
been reported, with inhibition of PBMC immune responses in mixed lymphocyte 
reactions (MLR) and phytohemagglutinin (PHA) activation assays (Wolbank et al. 2007; 
Magatti et al. 2008). The inhibitory effect of hAMCs was reported to be comparable to 
that of hAECs. However, there was no agreement as to whether the immunosuppression 
was mediated through soluble factors or by direct cell-cell contact; as transwell culture 
(without direct cell-cell contact) abolished the inhibitory effect in one study (Wolbank et 
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al. 2007) but not in another two studies (Ennis et al. 2008a; Magatti et al. 2008). 
Magatti’s group recently has also reported an inhibitory effect of hAMCs on dendritic 
cell differentiation and maturation (Magatti et al. 2009), suggesting an involvement of 
cell cycle arrest together with modulation of inflammatory cytokines.  
In vivo studies of hAMCs are only just beginning to be reported. A recent 
xenotransplantation study reported that hAMCs survived for at least 2 weeks and reduced 
fibrosis after injection into infracted myocardium of immunocompetent rats (Tsuji et al. 
2010). No immunossupressant was used. The transplanted hAMCs were shown to engraft 
in the host myocardium with signs of in vivo transdifferentiation into cardiomyocytes. 
Interestingly, these cells also secreted soluble HLA-G in vitro and in vivo, which could be 
detected in the rat serum. However, there was no correlation between the number of 
engrafted cells and serum HLA-G concentration. This was the first time that HLA-G was 
reported to be involved in immune modulation in a cell transplantation scenario. Its role 
and mechanisms of action definitely merits more investigation.  
 
2.4.4 Umbilical cord blood stem cells  
 The umbilical cord is one of the extraembryonic tissues readily available after 
parturition. Cord blood has been the source of the best characterized and prototypical 
fetal/neonatal stem cells. Hematopoietic stem/progenitor cells have been isolated from 
the cord blood since 1974 (Knudtzon 1974), and have been used to reconstitute the 
hematopoietic system in clinical application since 1989 (Broxmeyer et al. 1989; 
Gluckman et al. 1989). Cord blood usually has similar proportions of hematopoietic 
progenitor cells as the bone marrow, while having some differences with particular 
subsets of cells. It has been shown that hematopoietic progenitors from the cord blood are 
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more proliferative compared to those from the bone marrow, probably due to a higher 
frequency of more primitive multipotent HSCs in the cord blood (Hows et al. 1992; Lu et 
al. 1993). Cord blood HSCs have been extensively studied and widely used in clinical 
treatments and cord blood banks have developed since the mid to late 1990s. Moreover, 
cord blood cells are efficient gene transfer targets and their use in gene therapy has been 
tested in patients since 1995 (Kohn et al. 1995). 
Currently the therapies using cord blood HSCs are limited to the treatment of 
blood and immune diseases. Researchers have also tried to isolate MSCs from cord blood 
but unfortunately, cord blood does not seem to be a very rich source of MSCs. Previous 
attempts to isolate MSCs from the cord blood have either failed (Mareschi et al. 2001; 
Wexler et al. 2003), have an unpromising success rate (Kogler et al. 2004) or have 
demonstrated a low frequency of mesenchymal progenitors in cord blood (Erices et al. 
2000; Goodwin et al. 2001). Bieback et al. suggested that stringent criteria for parameters 
like the harvest time, volume and cell count are necessary for successful enrichment of 
the MSCs from the cord blood (Bieback et al. 2004). In contrast, isolation of MSCs from 
Wharton’s jelly has been more successful.  
 
2.4.5 Wharton’s jelly stromal cells  
 The human umbilical cord is present from day 26 of gestation and rapidly grows 
to the full length of about 50 cm at birth. It has been speculated that there is a 
mesenchymal precursor cell population within the umbilical cord that gives rise to the 
Wharton’s jelly connective tissue. Wharton's jelly is a gelatinous substance within the 
umbilical cord which protects the two arteries and one vein running through it. The 
Wharton’s jelly is largely made up of mucopolysaccharides and is covered by amniotic 
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epithelium. Based on structural and functional studies, it has been shown that the 
umbilical cord has a tissue compartmentalization with different cellular characteristics 
and extracellular matrix (ECM) components. These include amniotic epithelium, 
subamniotic stroma, intervascular stroma, perivascular stroma, and vessels, from outer to 
inner (Nanaev et al. 1997).  
 The distinction of these regions have been based on very complicated microscopic, 
ultrasonic and immunohistochemical analysis. Separation of these regions for cell 
isolation is technically extremely challenging and has not been achieved. Cho et al. 
minced and digested the umbilical cord after cord blood has been drained (Cho et al. 
2008). La Rocca et al. also used the whole cord tissue but did not employ enzymatic 
digestion. They let the cells grow out based on their migratory properties (La Rocca et al. 
2009). With the simple dissection procedures used, a heterogeneous cell population from 
a few different regions might have been isolated and analyzed. Weiss et al. (Weiss et al. 
2006) and Karahuseyinoglu et al. (Karahuseyinoglu et al. 2007) have both removed the 
umbilical blood vessels and extracted cells from the remaining tissues. Some other 
researchers have made efforts to extract cells more specifically from the targeted regions. 
Sarugaser et al. obtained umbilical cord perivascular cells (UCPVC) from the areas 
surrounding the blood vessels, after removal of the umbilical cord epithelium (Sarugaser 
et al. 2005). Kita et al. isolated cells from the cord lining membrane, which consists of 
the amniotic epithelium and the subamniotic stroma (Kita et al. 2010). For the latter two 
studies, the cells may not be categorized as Wharton’s jelly cells and will be reviewed in 
later sections.  
This area of research has been troubled by the heterogeneous cell populations that 
exist in the Wharton’s jelly, and the various differing isolation and culture techniques 
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used in different laboratories. There have been a few different terms used to name these 
cells, such as Wharton’s jelly MSCs, umbilical cord matrix stem cells and umbilical cord 
stromal cells. In general, all these stem cells adhere to culture plastics and are 
mesenchymal in nature. For consistency, they will be uniformly addressed as Wharton’s 
jelly MSC (WJ-MSC) in this literature review. 
Some researchers have described the WJ-MSCs as “primitive MSCs”, suggesting 
that they have superior differentiation potential over the adult MSCs (Baksh et al. 2007). 
The multipotent cells from Wharton’s jelly were able to differentiate into cell types of all 
three germ layers including adipocytes, osteoblasts, chondrocytes, neuroglial-like, 
hepatocyte-like, cardiomyocyte-like cells (Wang et al. 2004; La Rocca et al. 2009), 
oligodendrocyte progenitor-like cells (Zhang et al. 2010), pancreatic islet-like cells (Chao 
et al. 2008), and hepatocyte-like cells (Anzalone et al. 2010). In addition, WJ-MSCs 
express classical stem cell markers, such as Nanog and Oct3/4A (La Rocca et al. 2009).  
 The yield and number of stem cells obtainable from the Wharton’s jelly has been 
difficult to determine due to lack of consistent standards of extraction and definition of 
the stem cells. Some researchers have estimated the cell yield to be 10-15x103 per 
centimeter of cord (Karahuseyinoglu et al. 2007; Ennis et al. 2008b). However, this 
represents the number of viable adherent cells from the primary culture rather than a 
purified population of multipotent stem cells. 
 Although there have been only limited in vivo studies involving transplantation of 
the Wharton’s jelly derived MSCs, the results have been encouraging. Weiss et al. 
transplanted undifferentiated human WJ-MSCs into the brains of rats in a Parkinsons 
disease model and reported amelioration of apomorphine–induced behavior (Weiss et al. 
2006). However, they were able to detect human cells in the rat brain section after 2 days 
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post-transplantation only and not any longer. This could be due to the very small number 
of transplanted cells (1,000) and xenorejection without immunosuppressive drugs. Koh et 
al. implanted the in vitro neuronal-differentiated human WJ-MSCs into the damaged 
hemisphere of ischemic stroke rats (Koh et al. 2008). The rats were all treated with 
immunosuppressive drugs. Human cells could be detected at the lesion site 21 days post-
transplantation. They also reported improved neurobehavioral function and reduced 
infarct volume compared to control rats. This, however, could possibly be attributed to 
the neuroprotective effects of the MSCs rather than to their differentiation into 
functionally active neuronal cells. Campard et al. injected undifferentiated human WJ-
MSCs into the spleen of hepatectomized SCID mice and detected engrafted and 
differentiated human cells in the recipient livers for up to 6 weeks (Campard et al. 2008). 
Survival of transplanted human WJ-MSCs into the immunoprivileged site of the rat 
spinal cord for 16 weeks has been reported recently (Yang et al. 2008) without the need 
of immune suppression. They reported that transplanted animals had significantly 
improved locomotion and better axonal regeneration. Taken together, these in vivo 
studies have shown a therapeutic potential for WJ-MSCs. 
 A few studies have investigated the immunological properties of WJ-MSCs. 
Human WJ-MSCs have been reported to express moderate levels of MHC class I, but no 
MHC class II antigens (Weiss et al. 2008) and no co-stimulatory surface antigens CD40, 
CD80 and CD86 (Weiss et al. 2008). Cho et al. has reported similar results about MHC I 
and II expression, and reported inhibition of MLR in porcine WJ-MSCs (Cho et al. 2008). 
Weiss et al. has also reported that WJ-MSCs inhibited mitogen induced rat splenocyte 
proliferation and alloantigen induced MLR responses in vitro. Interestingly, this study 
has also analyzed expression of the two soluble isoforms of HLA-G in the WJ-MSCs. 
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WJ-MSCs expressed mRNA of isoform 6 but not isoform 5 (Weiss et al. 2008).  HLA-G 
mRNA expression in WJ-MSCs has also been reported by La Rocca et al., without 
further information on the isoforms (La Rocca et al. 2009).  
 
2.4.6 Umbilical cord perivascular cells 
The umbilical cord perivascular cell (UCPVC) is a relatively new cell type first 
isolated and characterized in 2005, by a research group from Toronto, Canada (Sarugaser 
et al. 2005). To date, there have been only a handful of publications about this cell.  
 The researchers have designed steps for dissecting and digesting the umbilical 
cord to remove the lining membrane and to avoid digesting the endothelial cells from the 
vessels. These procedures help to define the origin of UCPVCs in a more specific 
anatomical region. Furthermore, the term “perivascular” was suggested based on their 
expression of 3G5, α-actin, desmin, and vimentin, which was thought to resemble 
pericytes.  However, the pericyte marker 3G5 has also been detected in MSCs (Khan et al. 
2010). It is unclear how distinctive UCPVC and WJ-MSC are, but comparative study 
with bone marrow derived MSCs has reported that UCPVCs have higher proliferation 
potential, higher CD146 expression (an endothelial cell antigen also expressed at the 
surface of pericytes) than the MSCs and similar transfection efficiency (Baksh et el. 
2007).  
 UCPVCs also express a panel of MSC markers including CD105, CD73, CD90, 
and CD44, and UCPVCs do not express HSC markers CD45 and CD34. In contrast to 
amniotic membrane derived cells and WJ-MSCs, UCPVCs do not express embryonic 
stem cell markers SSEA-4, Oct-4 or Nanog. HLA-G has not been detected in UCPVCs, 
either. UCPVCs have spontaneous osteogenic differentiation (Sarugaser et al. 2005), and 
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have been induced to differentiate into all five mesenchymal lineages in culture: 
fibroblast, bone, cartilage, fat and muscle (Baksh et al. 2007). 
 UCPVCs are unique in that a subpopulation of these cells do not express any 
MHC-I or MHC II (MHC-/-) antigens, hence these cells may be potentially non-antigenic. 
In addition, the portion of MHC-/- cells increases over passages, reaching 95% by 
passage 5 (Sarugaser et al. 2005). However, there have not been in vivo studies to show 
the function of this phenotype or whether it was maintained following differentiation.  
 In vitro immunological studies have indicated that UCPVCs have similar 
immunomodulatory properties with MSCs (Ennis et al. 2008a). These cells were shown 
to inhibit peripheral blood lymphocyte proliferation in MLR and significantly decreased 
CD25 and CD45 expressions in these lymphocytes. This effect was not affected by the 
transwell. Hence it was suggested to be mediated by soluble factors.  
 
2.4.7 Umbilical cord lining cells 
 Recently, Prof. Phan Toan Thang from National University of Singapore isolated 
stem cells from the subamniotic region and amniotic epithelium of the umbilical cord 
(Kita et al. 2010). The amniotic epithelium is derived from the embryonic ectoderm, 
whereas Wharton’s jelly develops from the extraembryonic mesoderm (Drews 1995). 
Prof. Phan’s work has been the first approach to isolate cells from the cord lining 
membrane, by pre-removing the blood vessels, intervascular and perivascular parts of the 
Wharton’s jelly. Both mesenchymal and epithelial cells have been derived from the cord 
lining membrane. 
Characterization of the cord lining mesenchymal cells (CLMCs) has indicated that 
they are multipotent stem cells, resembling Wharton’s jelly MSCs and bone marrow 
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MSCs. Surface marker profile of these cells has met the criterion of MSCs, with 
expression of CD10, CD13, CD44, CD73, CD90, CD105 and negligible levels of CD31, 
CD34 and CD45. However, the CLMCs differ from bone marrow MSCs, with negative 
staining for STRO-1. In addition, expression of CD14 has been detected, which was 
unusual because CD14 has been thought to be a marker of monocytes and macrophages. 
It was suggested that this might be associated with the immunological properties of these 
cells. Further investigations of these interesting findings have not been carried out nor 
reported.  
CLMCs have been reported to express several markers associated with 
pluripotency, such as Oct-4, Nanog, SSEA-4. They did not express the other embryonic 
stem cell markers SOX2, FGF-4, TERT, and REX1. It was suggested that this stem cell 
marker profile might indicate multipotency but these cells were distinct from ESCs. This 
has been supported by successful differentiation of CLMCs into adipogenic, osteogenic, 
and chondrogenic lineages. Additionally, these cells did not show anchorage-independent 
growth in soft agar, indicating an absence of tumorigenic properties.  
Recently, a study on adipogenic differentiation of the CLMCs has characterized 
the adipocyte-like cells derived from CLMCs in further detail (Cheong et al. 2010). 
Adipocyte-like cells generated under different glucose concentrations and insulin 
concentrations were shown to have distinct secretion profiles of the two major 
adipocytokines, leptin and adiponectin, which resembled adipocytes in either normal 
weight or obese individuals. Hence, the CLMCs derived adipocyte-like cells have been 
suggested as a potential in vitro model to study adipogenesis and obesity, and possibly as 
a drug discovery model for metabolic disorders.  
 47
The cord lining derived epithelial cells (CLECs) are characterized by expression 
of epithelial-associated markers, including several members of the cytokeratins, E-
cadherin, mucin-1 (epithelial membrane antigen), and adhesion molecules integrin-α6, -
α9, -β1, collagen-IV and laminin (Reza et al. 2011). CLECs have also been proposed to 
have stem cell characteristics, based on their expression of several known ES cell 
markers Oct-4, Nanog, SOX2, REX1 and SSEA-4 (Reza et al. 2010).  
CLECs spontaneously differentiated into keratinocyte-like cells in standard 
keratinocyte culture medium. These cord lining derived keratinocyte-like cells share 
almost the same characteristics at morphological, molecular and functional levels with 
neonatal primary keratinocytes (Ruetze et al. 2008). More recently, CLECs have been 
found to express several putative limbal stem cell markers. Transplantation of these cells 
resulted in successful reconstruction of the ocular surface in a limbal stem cell-deficient 
rabbit model (Reza et al. 2011). These results indicate the potential use of CLECs as a 
more easily accessible alternative to neonatal primary keratinocytes, limbal stem cells 
and autologous epithelial cells, in dermatological research, ocular surface regeneration 
and other clinical applications.  
Another area of interest regarding these cells that has not been investigated is 
whether cord lining cells possess similar immunoregulatory properties as cells derived 
from Wharton’s jelly or amniotic membrane. In vivo studies of cord lining cells have not 
been reported.  
The subject of investigation of this thesis was to study the properties of these cord 
lining derived cells, especially in regard to their immunological properties, and their 
potential use in cell transplantation. 
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The thesis therefore had these objectives: 
A) To characterize in detail the immunological features of the cord lining 
cells, especially in relation to the expression of HLA-G in its various 
isoforms. 
B) To utilize ex vivo assays to further study the immunoregulatory properties 
of the cord lining cells, and investigate the mechanism(s) of these 
properties, if present. 
C) To study the in vivo survival of these cord lining derived cells in an 
immunocompetent host. 
D) To carry out preliminary studies on the potential of these cord lining cells 
in cell/gene therapy. 
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Chapter 3  Materials and Methods 
3.1 Materials 
3.1.1 Primary cells and cell lines 
All cell cultures used in this study were maintained in tissue culture treated dishes 
or flasks, kept in 37°C cell incubator with 5% CO2, subcultured using a cell scraper or by 
trypsinization, and stored in liquid nitrogen when not in use for experiments. 1% 
penicillin/streptomycin were routinely used as antibiotics in all culture media. 
 
3.1.1.1 Cord lining epithelial and mesenchymal cells 
CLECs and CLMCs were isolated by my co-supervisor Prof. Phan Toan Thang 
and other researchers from CellResearch Corp, Singapore, as described previously (Kita 
et al. 2010; Sivalingam et al. 2010) (international publication number WO 2006/019357 
A1  and UK Patent GB2432166). Briefly, human umbilical cord tissues were obtained 
with informed consent after delivery. The cord lining tissue, where the cord lining cells 
were derived, consisted of the amniotic epithelium and the adjacent sub-amniotic region, 
which could be viewed in the schematic of the placenta and umbilical cord anatomy (Fig. 
3.1A). Steps of dissecting the cord lining tissues were: i) Carefully washed umbilical cord 
was cut transversely into inch-long sections. ii) Blood vessels and Wharton’s jelly (the 
matrix of umbilical cord) were removed using razer blades. iii) The outer lining 
membrane of the cord was rinsed and further dissected into small pieces (0.5 cm x 0.5 
cm) for primary tissue explant culture (Fig. 3.1B). 
Different growth media were formulated by researchers from CellResearch Corp, 
Singapore, for the propagation of CLECs and CLMCs in vitro. CLECs were cultured in 
Medium 171 (Cascade Biologics) supplemented with 50 μg/ml insulin-like growth factor-
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1, 50 μg/ml platelet-derived growth factor-BB, 5 μg/ml transforming growth factor-β1, 
and 5 μg/ml insulin (all from R&D Systems). For CLMCs, the culture medium was 
CMRL1660 medium (Invitrogen) containing L-glutamine and 10% fetal bovine serum 
(FBS) (Invitrogen).  
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A. Schematic drawing of the placenta and umbilical cord cross section, based on photos1 (for 
placenta) and histological pictures2 (for cord section). Part of the amniotic membrane was peeled 
off to show the chorion structure underneath. B. Schematic drawing illustrating the procedures of 
cord lining cells isolation, based on photos taken during the procedures (Kita et al. 2010).     
                                                           
1 Keith L. Moore, T. V. N. Persaud, Kohei Shiota. Figure 4-11, page 84. Color atlas of clinical embryology. 
2nd edition. Philadelphia : W. B. Saunders, 2000.  






3.1.1.2 Choriocarcinoma cell lines 
Human placental choriocarcinoma cell lines JEG3 and JAR were purchased from 
American Type Culture Collection (ATCC). Use of cell culture medium followed 
recommendations by the supplier. JEG-3 was cultured in DMEM containing 10% FBS. 
For JAR, the culture medium was RPMI-1640 containing 10% FBS. Demethylating agent 
5-aza-2’-deoxycytidine (Sigma) was added to the JAR cells at 100 μM for 72 hours to 
induce HLA-G expression (Moreau et al. 2003).  
 
3.1.1.3 Primary keratinocytes 
Human primary keratinocytes were isolated by my co-supervisor Prof. Phan Toan 
Thang, from normal adult skin samples removed in plastic surgery procedures, with 
informed consent and NUS-IRB approval. Cell isolation procedures had been described 
previously (Mukhopadhyay et al. 2005). Briefly, skin specimens were thoroughly washed 
and then digested with dispase 5 mg/ml in HBSS overnight at 4°C. The next day, the 
epidermis was carefully scraped off with a scalpel and placed in 0.25% trypsin/0.1% 
glucose/0.02% EDTA for 10 min at 37°C. Isolated single cells were seeded in 
keratinocyte culture medium (DMEM supplemented with 20% FCS, 10 ng/ml epidermal 
growth factor, 1 × 10−9 mol/L cholera toxin and 0.4 µg/ml hydrocortisone) at 
1 × 105 cells/cm2 for 24 hours before changing to commercial keratinocyte growth 
medium (Clonetics). 
 
3.1.1.4 Conditioned culture supernatants 
The conditioned culture supernatants were medium which had been used to 
cultivate cells for a period of time and contained soluble proteins secreted by the cells.  
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For cord lining cell cultures, conditioned culture supernatants were collected after 
48 hours of incubation, as 8 ml total volume from a 100 mm tissue culture dish. Before 
the incubation, cells were grown to confluency and rinsed three times to remove residual 
serum proteins. Then serum-free basal medium was added to be conditioned.  
As the conditioned culture supernatants were collected, cell debris was removed 
by centrifugation at 1,800 rpm, 4°C, for 10 mins. Then the supernatants were aliquoted 
and kept frozen in -30°C until use.  
The conditioned culture supernatants were later concentrated using amnicon 
columns (10 kDa cutoff) for western blot analysis, added into other cell cultures in the T 
cell proliferation assays, or measured by ELISA for specific protein concentrations. 
For MLR cultures, conditioned culture supernatants were collected at day 3 and 
day 7 of the MLR reaction period. Around 100-200 µl were collected from a total volume 
of 1.5 ml per well, with efforts to avoid disturbing the MLR cultures. The aliquots were 
immediately frozen in -80°C until measured in the multiplex cytokine array.   
   
3.1.2 PCR primers 
Primers used for PCR experiments were designed using online program primer 3 
(v. 0.4.0) (Rozen et al. 2000) at http://frodo.wi.mit.edu/primer3/. Refseq mRNA 
sequences were downloaded from NCBI sequence viewer (NM_002127 for HLA-G, 
NM_005516 for HLA-E, NM_001101.3 for human β-actin, NM_001025366 for human 
VEGF and NM_000207 for human insulin). All the primer pairs were designed to cross 
exons, to avoid false positive caused by genomic DNA contamination. The primer 
sequences were also checked using BLAST to ensure specificity. Primer sequences are 
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listed in Table 1. The oligonucleotides were synthesized and supplied by 1st BASE Pte 
Ltd, Singapore. 
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3.1.3 Gene transfer constructs 
3.1.3.1 Gene expression 
Lentiviral vector pWPT-eGFP used for survival studies in immunocompetent 
mice was a kind gift from Prof. Didier Trono (University of Lausanne, Switzerland). 
pWPT-DsRed2 was constructed by my co-supervisor Dr. Gan Shu Uin, using the same 
vector backbone. Expression of eGFP and DsRed2 were under the control of a ubiquitous 
human elongation factor 1-α (EF1α) promoter.  
Lentiviral vector HMD-INS(fur)-eGFP used for ex vivo gene therapy of STZ 
induced diabetic mice was a kind gift from Prof. Ann Simpson (University of 
Technology, Sydney, Australia) (Ren et al. 2007). The HMD vector was a human 
immunodeficiency virus (HIV)-based lentiviral vector with modifications to have an 
HIV/murine stem cell virus (MSCV) hybrid long terminal repeat (LTR) (Choi et al. 
2001). The HIV/MSCV hybrid LTR served as the promoter and controlled the 
constitutive expression of two genes. The transfer vector carried human proinsulin cDNA 
modified to have furin consensus cleavage sequences. In this way the furin-cleavable 
proinsulin would be efficiently processed in CLECs in the constitutive secretory pathway 
(Groskreutz et la. 1994). The same vector also expressed eGFP bicistronically with an 
internal ribosomal entry site (IRES).  
 
3.1.3.2 Gene silencing 
In order to shut down HLA-G expression in CLECs, the cells were transduced by 
MISSION shRNA Lentiviral Transduction Particles (Sigma). Five shRNA sequences 
targeting different regions of the HLA-G coding sequences were designed by The RNAi 
Consortium (TRC) algorithms (Table 2).  
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Table 2 shRNA sequences for HLA-G gene silencing 
















































Two strains of mice were used in this study: normal balb/c mice and severe 
combined immunodeficiency (SCID) mice. The normal balb/c mice were supplied by 
Centre for Animal Resources, Singapore. The SCID mice had a genetic background of 
CB17/IcrHanHsd-Prkcdscid and were supplied by Biological Resource Centre, 
Singapore. They were housed at Animal Holding Unit (AHU), National University of 
Singapore. The mice were held in individually ventilated cages at constant temperature 
(24-26°C) and humidity (30-50%). SCID mice were kept in sterile, animal biosafety level 
2 (ABSL2) facilities. Normal balb/c mice were also transferred to and kept in ABSL2 
facilities for cell transplantation and the following experiments. All the mice were 
transported in at around 6-8 weeks of age. One to two weeks were allowed for the 
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animals to settle, accommodate and receive the necessary pre-transplantation treatment if 
any. Xeno-transplantation of human cells was carried out on mice at 8-10 weeks of age. 
 
3.1.6 Antibodies and kits 
Anti-HLA-A, B, C (BD Pharmingen) 
Anti-HLA-DR (BD Pharmingen) 
Anti-HLA-E (clone MEM-E/02, Abcam,) 
Anti-HLA-G (clone 4H84, BD Pharmingen) 
Anti-HLA-G, functional grade (clone 87G, Exbio, Czech) 
Anti-pan-cytokeratin-Alexa Fluor 488 (clone AE1/AE3, ebiosciences) 
Anti-human CD44-FITC (ebiosciences) 
Anti-human ICAM-1/CD54-APC (BD Pharmingen) 
Anti-human CD104-Alexa Fluor 647 (ebiosciences) 
Anti-human CD4-PB (ebiosciences, biolegend)  
Anti-human CD4-FITC (ebiosciences, biolegend) 
Anti-human CD25-PB (ebiosciences, biolegend) 
Anti-human CD25-APC (ebiosciences, biolegend) 
Anti-human Foxp3-PE (ebiosciences) 
Anti-GFP (Chemicon) 
Anti-human vimentin (clone V9, Zymed) 
Anti-human/mouse insulin (Cell signaling) 
Annexin V-APC (BD Pharmingen) 
RNeasy mini kit (Qiagen)  
Treg staining kit (eBioscience) 
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Bio-Plex Pro Human Cytokine Reagent kit (Bio-rad) 
C-peptide ELISA kit (Linco, Millipore) 
 
3.2 Methods 
3.2.1 Colony formation and rhodamine staining 
The cord lining cells were trypsinized, resuspended in culture medium and 
counted with a hemacytometer. A few dilutions each followed by cell counting were 
performed until the desired cell concentration was reached. 100 cells were seeded into 
one 100 mm tissue culture dish. Cells were kept in 37°C incubator with 5% CO2 and 
monitored over 14 days with appropriate medium changes. On day 14, cells were fixed 
with 4% paraformaldehyde for 30 mins at room temperature and then stained with 0.1% 
rhodamine (Sigma-Aldrich) for 30 mins. 
 
3.2.2 Molecular biology techniques 
3.2.2.1 Protein extraction and quantification 
For protein extraction, cultured cells were treated with cell lysis buffer containing 
10 mM Tris-HCl (pH 7.4), 0.5% Triton X-100, 150 mM Sodium Chloride, 1mM EDTA, 
0.5% Nonidet P-40, 0.25mM Sodium Vanadate and 1 mg/ml protease inhibitor cocktail 
(Boehringer-Mannheim, Germany) for membrane solubilization. Briefly, culture medium 
was completely removed from the dish or flask by aspiration and gentle tapping on clean 
paper towel. The lysis buffer described as above was then added on top of the cell layer. 
The cells were scraped off the culture vessel, homogenized through a 27 G needle. All 
these steps were carried out with samples kept on ice or in a cold room, to minimize 
protein degradation.  
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Soluble fractions of the cell lysates were collected as supernatants after 
centrifugation at 11,000 rpm, 5 mins, 4oC. Protein concentrations were determined by 
Bradford protein assay (Bio-rad), following manufacturer’s instructions. Then the protein 
samples were aliquoted and stored in -30°C until use. 
Protein samples were also prepared from conditioned culture supernatants. 
Conditioned culture supernatants were concentrated 200-500 times with the Amicon 
centrifugal filtration device (Millipore) by passing water, salt and other smaller molecules 
through a 10 kDa cutoff membrane. This was done at 3,700 rpm, 4°C. Then the protein 
samples were quantified, stored and analyzed the same way as the cell lysate extractions. 
 
3.2.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to separate proteins for western blot analysis. This is a 
denaturing gel which separates the proteins by their molecular weights.  Briefly, a 100 µg 
protein sample was mixed with 5 X bromophenol blue loading dye at 4:1 (v/v) and 
incubated in boiling water bath for 5 mins. The loading buffer contained 60 mM Tris-
HCL (pH6.8), 20% glycerol, 2% SDS, 0.01% bromophenol blue and 5% β-
mercaptoethanol. The β-mercaptoethanol was added freshly before use. Gel 
electrophoresis was done with the Bio-rad PROTEAN II xi vertical electrophoresis cells 
system, with freshly casted 14% acrylamide gel containing 375 mM Tris-HCL, 0.1% 
SDS, and 0.1% ammonium persulfate, 0.05% TEMED for gel polymerisation. Resolving 
gel size is about 12 cm x 16 cm x 1.5 mm. A 15 well x 1.5 mm comb with a volume of 
221 µl per lane was usually used, which allowed loading protein samples up to around 
180 µl per lane.  
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3.2.2.3 Western blot 
After the gel electropheresis, proteins were electroblotted (wet) onto a 
nitrocellulose membrane in a buffer containing 25 mM Tris base, 192 mM Glycine and 
20% v/v methanol. Methanol was added freshly before use. The electroblotting process 
was done overnight at 29 volts in the Bio-rad Trans-Blot Cell.  
 After the electroblotting, rapid reversible detection of protein bands was routinely 
done with Ponceau S staining. The staining was then removed with water washes and the 
membrane was blocked in 5% skimmed milk in Tris buffered saline (TBS) with 0.25% 
Tween 20 for 2 hours at room temperature. The TBS 0.25% Tween buffer was used 
throughout the following steps for incubation and washes of the membrane. All the 
incubating and washing steps for western blot were done on a shaker at around 70-100 
rpm.  
 Primary antibodies and horseradish peroxidase-conjugated secondary antibodies 
were diluted in TBS Tween with 1% skimmed milk. Incubation with primary and 
secondary antibodies each took 1 hour at room temperature, each followed by 4X washes. 
Chemilumninescence reagents (PerkinElmer) were added for 1 min. And the membrane 
was exposed to a photographic film (Kodak) for 1-15 mins away from light. Finally, the 
blots were visualized with a chemiluminescence-based photoblot system (Amersham 
Biosciences). 
 
3.2.2.4 Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cultured cells using Qiagen RNeasy Mini kit, 
following the manufacturer’s instructions. The total RNA was then quantified with 
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Nanodrop ND-1000 spectrophotometer. All the RNA and cDNA samples were stored in -
30°C until use.  
Reverse transcription was done with SuperScript III First-Strand Synthesis 
System (Invitrogen), using 2 µg of total RNA primed with 2.5 µM oligo dT (1st base 
oligo, Singapore) for 1 hour at 50oC, with a reaction volume of 20 µl. The reaction was 
stopped by heating at 80oC for 5 mins.   
PCR was done using an MJ Research PTC-100 thermal cycler, in a total volume 
of 50 µl with 2 µl RT product, 200 µM of each dNTP (Promega), 0.4 µM of each primer 
(1st base oligo, Singapore), 1.5 mM MgCl2, 10 µl 5X Green GoTaq Flexi Buffer and 1.25 
units GoTaq Flexi DNA polymerase (Promega).  PCR cycle conditions were 45 s at 95oC, 
45 s at Ta3 and 45 s at 72oC, for 40 cycles, with initial denaturation at 95oC for 2 mins 
and final extension at 72oC for 5 mins. β-actin cDNA was used as a control and amplified 
with 30 cycles of PCR.   
 
3.2.2.5 Agarose gel electrophoresis 
PCR products were separated by length using agarose gel electrophoresis. 1.2% 
agarose gel was made by dissolving 0.72 mg agarose into 60 ml Tris-acetate-EDTA 
(TAE) buffer using microwave heating. The GelRed™ nucleic acid stain (Biotium) was 
added and mixed well with the gel as it cooled down to around 60°C. Then the gel was 
poured into the gel cast and left to set.  
 10-20 µl of cDNA products from the PCR were mixed with loading buffer 
(Invitrogen) and added into the wells. 1 kb plus DNA ladder (Invitrogen) was used along 
                                                           
3 Ta was the annealing temperature and was decided according to the melting temperature (Tm) of each 
primer set.  
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with the test samples. Gel electrophoresis was done in TAE buffer in a Mini-Sub Cell GT 
system (Bio-rad), at 70-90 volts until bands of interest were properly separated.  
 Visualization of the bands was done on a UV transilluminator (Wealtec). And 
images were captured by AlphaDigiDoc RT gel documentation system (Alpha Innotech, 
Cell Biosciences). 
 
3.2.3 Flow cytometry 
CLECs were harvested from culture dishes by trypsinization and washed with 
PBS + 2% FBS.  1 x 105 to 1 x 106 cells were incubated with fluorophore-conjugated 
antibodies in a volume of around 100 µl, for 30 min at 4oC. The cells were then washed 
and fixed with 1% paraformaldehyde (PFA) and analyzed on Dako-Cytomation CyAn 
ADP flow cytometer within 24 hours.  
A fix/permeablization step was utilized when intracellular staining was required. 
Permeabilization buffer from the Treg kit (eBioscience) was used for Foxp3 staining, 
following the manufacturer’s instruction. For staining of other intracellular antigens, cells 
were fixed with 2% PFA for 15 mins and permeablized with 0.5% saponin (Sigma-
Aldrich) in PBS+10% FBS for 20 mins at room temperature, before incubation with the 
antibodies.  
Annexin V-APC was used to label apoptotic cells with fluorescence. Similar to 
the immunostaining described in the previous section, conjugated annexin V were added 
into 100 µl cell suspension in an annexin V binding buffer containing 10 mM 
Hepes/NaOH (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2. Incubation was done in 15 
mins at room temperature. No fixation step was used and live cells were analyzed strictly 
within an hour after the staining. 
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Cells were kept away from light during the staining and flow cytometry. Isotype 
controls were used accordingly for every flow cytometry experiment. 
Flow cytomtry data analysis was done using Summit V4.3 software (Dako). 
Fluorescence compensation for multicolor staining was carried out manually, according 
to single stained controls. Cell numbers were normalized when different samples were 
compared in an overlaid histogram.  
 
3.2.4 Isolation of the immune cell populations 
Peripheral blood or buffy coat of healthy volunteers was obtained with informed 
consent under an approved protocol from the NUS institutional review board (IRB). 
Sodium citrate was added to a final concentration of 0.4% to prevent coagulation.  
 
3.2.4.1 Density gradient centrifugation 
Human PBMCs were isolated using Lympholyte-H density gradient separation 
medium (Cederlane), following the manufacturer’s instructions. Briefly, blood samples 
were diluted with equal volume of medium and buffy coat samples were diluted at least 
five times. These were then carefully layered onto Lympholyte-H in a centrifuge tube, 
with efforts to avoid mixing at the interface. The tube was then centrifuged for 20 mins at 
600 g, at room temperature, with minimum acceleration and deceleration. The white cell 






3.2.4.2 Magnetic-activated cell sorting (MACS) 
Separation of the immune cell populations by surface markers was done in a 
QuadroMAC Separator with LS columns (Miltenyi Biotech), following the 
manufacturer’s instructions. Peripheral blood monocytes were positively selected from 
the PBMCs using anti-CD14 microbeads (Miltenyi Biotech). T lymphocytes were 
isolated from the CD14-depleted PBMCs using anti-CD4 or anti-CD8 microbeads.  
Dendritic cells were generated by culturing the monocytes in 100ng/ml GM-CSF 
and 1000 U/ml IL4 for 7 days in DMEM with 10% human AB serum (Sallusto et al. 
1994) (Cambrex).   
 
3.2.5 Stimulated T cell proliferation 
3.2.5.1 Mitogen stimulation assay 
Freshly isolated PBMCs were seeded into 96-well plate at 2 x 105 cells per well 
and pulsed with 2 µg/ml phytohaemagglutinin (PHA) (Sigma-Alldrich) for 48 hours. Cell 
proliferation was then measured using the [3H] thymidine incorporation assay.   
48-hour conditioned culture supernatants incubated with equal numbers of CLECs 
or CLMCs were added to half the final volume of the PBMC cultures. Control wells were 
added with fresh media to the same volume.  
 
3.2.5.2 Mixed leukocyte reaction (MLR) 
Peripheral blood monocyte-derived DCs and T cells (CD4+ unless otherwise 
stated) from two genetically unrelated donors were co-cultured to generate allogeneic 
reactions. DCs were mitotically inactivated by Mitomycin C (15 µg/ml) (Sigma-Alldrich) 
treatment prior to MLR culture, to ensure that the measured proliferation was restricted to 
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T cells. T cells were freshly isolated on the day of MLR and mixed with DCs at a ratio of 
5:1. The mixed cells were then cultured for 7 days in DMEM with 6.67% human AB 
serum, in the presence of 5 U/ml recombinant IL2 (iDNA Biotech). 
 To study the immunogenicity of cord lining cells using this in vitro assay, either 
the conditioned culture supernatants or the cord lining cells were added into the MLR 
cultures, as described below. Unstimulated T cell alone cultures were used as control for 
background level of proliferation. 
 
3.2.5.2.1 MLR in 96-well plate setting  
MLR was carried out in 96-well microtitre plates to test the effects of cord lining 
cells conditioned culture supernatants. Each well contained 2 x 105 T cells and 4 x 104 
DCs, with the addition of conditioned culture supernatants or control medium to half of 
the final volume. Proliferations of the T cells were measured on day 7 of MLR, using the 
[3H] thymidine incorporation assay.  
 
3.2.5.2.2 MLR in 24-well plate setting  
MLR was carried out in 24-well plates to co-culture with the cord lining cells. 
CLECs or CLMCs were seeded into the wells at a density of 50,000 cells/well (unless 
otherwise noted), one day before the MLR. Then on the day of MLR, T cells and DCs 
were added directly into the culture wells or placed into a 0.4 µm pore size transwell (BD 
falcon) (Fig. 3.2). Cell numbers were 1 x 106 T cells and 2 x 105 DCs for each well. 




3.2.5.2.3 CLEC titration experiments 
To investigate the dose-function relationship in the CLEC effects on the MLR 
proliferation, CLEC numbers in the co-cultures of MLR were diluted 2 x, 5 x and 10 x to 
a final concentration of 5,000 cells per well. Cell numbers of T cells and DCs were both 
fixed as in the 24-well plate setting. The results were assessed with the CFSE cell 
proliferation assay. 
 
3.2.6 [3H] thymidine incorporation assay 
Tritiated thymidine (GE Healthcare) was added to a final concentration of 0.5 
µCi/well in the 96-well plate on the 7th day of MLR or on the 2nd day of the mitogen 
stimulation assay. Cells were incubated for 6 hours for the [3H] thymidine to incorporate 
into the DNA of actively dividing cells. The radioactivity of labeled cells was measured 
by harvesting the T cells onto UniFilter plates (PerkinElmer), drying for 1 hour at 60oC 
and analyzing on a Beckman TopCount liquid scintillation plate reader (Beckman). This 
assay was done in triplicate wells.  
 
3.2.7 CFSE cell proliferation assay 
T cells were stained with the membrane permeable dye carboxyfluorescein diacetate, 
succinimidyl ester (CFDA, SE) (Invitrogen) prior to MLR, at 2 M for 10 mins at 37oC. 
CFSE was then processed by intracellular enzymes to become the highly fluorescent 
carboxyfluorescein succinimidyl ester (CFSE), which was retained inside the cell and 
diluted during cell division. T cells were harvested on the 7th day of MLR and 
counterstained with anti-CD4 and other antibodies prior to analysis by flow cytometry. 
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Day -7: CD14+ monocyte isolation from fresh blood (donor A), followed by differentiation into DCs. 
Day -1: Seeding of CLECs. 
Day 0: CD4+ and/or CD8+ T lymphocyte isolation from fresh blood (donor B). DCs and T cells 
were added into CLEC or control wells to start the MLR.  
Day 7: End of MLR. Cells were harvested for analysis.  
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3.2.8 Multiplex cytokine assay 
Conditioned culture supernatants from CLEC and MLR cultures were stored in -
80°C and were thawed only once for this assay. Human cytokines were measured using 
Biorad multiplex cytokine assay systems (Bio-Rad Laboratories) with simultaneous 
detection of several human cytokines in a single sample (Floto et al. 2006). This assay 
was done is duplicate wells, following the manufacturer’s instructions. Briefly, 50 µl of 
conditioned supernatants per well were incubated with an array of fluorescently dyed 
beads which were covalently coupled with antibodies against the cytokines of interest, in 
a 96-well filter plate. After 30 mins incubation at room temperature, the beads were 
carefully washed and biotinylated detection antibodies were added. The cytokines of 
interest were thus sandwiched between the beads and the detection antibodies. More 
washes were done to remove excessive detection antibodies. Finally a streptavidin-
phycoerythrin reporter complex was added to bind to the biotinylated detection 
antibodies on the bead surface.  
Bio-Plex 200 multiplex array system with high-throughput fluidics (Bio-rad) was 
used to read the beads with lasers. Individual cytokines were identified corresponding to 
the specific dye color of the beads. Intensity of fluorescence detected on the beads 
indicated the relative quantity of the cytokines of interest in the tested samples. 
Data analysis was carried out using 5-parametric-curve fitting Bio-Plex Manager 






3.2.9 Stable transduction using lentivial constructs 
Production of the lentiviral particles and infection of the JEG3, CLMCs, CLECs 
and keratinocytes were all performed by my co-supervisor Dr. Gan Shu Uin, following 
Prof. Trono’s previously described protocols (Nguyen et al. 2005).  
Briefly, the lentiviral vector stocks were generated by calcium phosphate 
mediated transient co-transfection of three plasmids into 293T cells: the transfer vector 
plasmid, the packaging plasmid pCMVΔR8.91, and the VSVG envelop protein-coding 
plasmid pMD.G.  
The viral supernatants were harvested in the respective growth media of JEG3, 
CLMCs, CLECs and keratinocytes and then added to the respective cell cultures with 
multiplicity of infection (MOI) ranging from 10-30 and in the presence of 8 µg /ml 
polybrene. JEG3 cells were further selected using 1 μg/ml puromycin for about one week 
till the untransduced cells were cleared.  
 
3.2.10 In vivo studies 
3.2.10.1 Xenotransplantation for survival study 
Normal immunocompetent Balb/c mice were used for assaying the survival of 
CLECs and CLMCs in vivo under conditions of acute rejection. Human primary 
keratinocytes were used as a control for CLECs. Lentiviral transduction was used to 
make the cells express different fluorescent genes: CLEC-DsRed2, CLMC-eGFP and 
keratinocyte-eGFP, respectively.  
The fluorescent cells were transplanted as a monolayer on a porous polyethylene 
phthalate (PET) membrane. Cells were seeded 1 day prior to transplantation at an 
identical seeding density of 2 x 105 cells/graft. Mice were anesthetized and a 1-2 cm 
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incision in the skin was made on the dorsal side. Three pieces of graft per mouse were 
inserted subcutaneously, followed by suturing. Grafts were removed at time points of 12 
hours, 48 hours, 14 days and 21 days to assess cell survival by fluorescent microscopy. 
To establish re-cultures, explanted graft was washed in PBS with 5% antibiotic 
antimycotic, minced and trypsinized for 5 min at 37°C.  
 
3.2.10.2 CLEC-based ex vivo gene therapy 
SCID mice (CB17/IcrHanHsd-Prkdcscid) were treated with streptozocin (STZ) to 
induce diabetes-like hyperglycemia. Freshly prepared STZ was injected intraperitoneally 
at a single dose of 180 mg/kg after 4 hours of fasting. Mice with blood glucose levels 
above 14 mM (252 mg/dl) for at least three consecutive days were considered stably 
hyperglycemic and used for transplantation experiments.  
Mice of the treatment group received an i.p. injection of insulin-expressing 
CLECs at 1x107 cells per mouse in 250 µl. Equal numbers of uninfected CLECs or equal 
volumes of RPMI 1640 medium (used for cell suspension) were injected into mice of the 
respective control groups.  
Blood glucose was monitored from the tail vein using Accu-Chek Active glucose 
meter (Roche Diagnostics), daily in the first week post cell injection and twice a week 
afterwards until the end of experiment. Body weight of each mouse was measured twice a 
week. Mice were euthanized at 3 weeks after transplantation. Mouse pancreas and 
engrafted CLECs were harvested for histological analysis. 
Serum samples were collected from each mouse at 24 hours, 48 hours, followed 
by once a week time points, through submandibular bleeding or tail vein bleeding. Serum 
C-peptide levels were measured with a C-peptide ELISA kit (Linco).  
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3.2.10.3 Anesthesia, euthanasia and necropsy 
 Anesthesia was performed before subcutaneous transplantation, by intra-
peritoneal injection of 0.1 ml of a mixture consisting of equal parts of Hypnorm (10 
mg/ml fluanisone and 0.315 mg/ml fentanyl citrate; Janssen Pharmaceutica, Berchem, 
Belgium) and Dormicum (5 mg/ml midazolam; Roche, Basel, Switzerland), diluted in 2 
parts water. 
Mice were euthanasized by CO2 asphyxiation in a gas chamber, at scheduled time 
points of the transplantation studies.  
For the subcutaneous transplantation, the graft could be identified in the shape of 
a plate, due to the membrane scaffold. It was carefully removed together with the 
adjacent skin or muscle tissues if attached.  
For the intraperitoneal injection, the peritoneum were thoroughly inspected for 
presence of transplanted cells or anything abnormal compared to the control medium 
injected mice. Pancreas tissue from each mouse was harvested for histological analysis.  
 
3.2.11 In vitro differentiation toward insulin-producing cells 
 In vitro differentiation of CLECs was attempted, following a previously reported 
protocol which was used to differentiated adipose tissue-derived MSCs into insulin-
producing cells (Timper et al. 2006). Briefly, the CLECs were cultured in a medium 
supplemented with nicotinamide 10 mM, activin-A 2 nM, exendin-4 10 nM, hepatocyte 
growth factor 100 pM, and pentagastrin 10 nM (all from Sigma). Basal medium was 
serum-free DMEM/F12 medium with 17.5 mM glucose, with B-27 serum-free 
supplement, N-2 Supplement and 1% penicillin/ streptomycin (all from Invitrogen). After 
7 days of induction, cells were harvested for RNA extraction, followed by RT-PCR 
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detection of insulin expression. The supernatants were also harvested and tested using a 
C-peptide ELISA kit (Linco). 
 
3.2.12 Immunohistochemistry  
3.2.12.1 Paraffin sections 
Tissue samples collected from the mice were fixed in 4% formaldehyde, 
processed in an automatic tissue processor (Leica TP1020) and embedded into paraffin 
blocks. Tissue sections were produced at 5 µM thickness using a manual rotary 
microtome (Leica).  
For immunostaining, paraffin sections of tissues were boiled in citrate buffer for 
antigen retrieval and then immunostained with anti-human vimentin antibody (clone V9, 
Invitrogen) or anti-GFP antibody (Chemicon), followed by visualisation using the 




Trypsinized and resuspended cells were spinned onto poly-L-Lysine coated glass 
slides using Shandon Cytospin 4 Cytocentrifuge. Briefly, 30,000-50,000 cells in 300 µl 
of medium suspension were loaded into each cuvette and spun at 800 rpm for 3 mins. 
Air-dried slides could be immunostained along with the tissue sections, using the same 






Microscopes were used for observing and imaging of experimental objects 
wherever appropriate. Bright field microscopy was used for colorimetric stained 
histological sections or cytospinned cells. Phase contrast microscopy was used for 
cultured cells and cell grafts with a membrane scaffold. Fluorescent microscopy was used 
for detection of fluorescent reporter gene labeled cells. These were all done on an 
Olympus IX70 microscope with an Olympus DP70 microscope camera.  
 Confocal microscopy was also used to visualize cell morphology within the graft. 
This was done with an Olympus FluoView FV300 confocal microscope.  
 
3.2.14 Statistical analysis 
Student’s t test with two-tailed p values was used for data analysis of T cell 
proliferation assays and ELISA. Bonferroni correction was applied where multiple 
comparison was involved. Friedman test was used to analyze data from multiplex 
cytokine arrays. Wilcoxon signed-rank test was used as post-hoc analysis, with 
Bonferroni correction. For the ex vivo gene therapy of STZ-induced diabetic mice, the 
statistical significance of differences between treatment and control groups were tested 
using general linear model for repeated measures, using SPSS version 17.0. Dunnett’s 
test was used as post-hoc analysis for pair-wise comparison among three groups. N 





Chapter 4  In Vitro Studies of Cord Lining Cells 
4.1 Introduction  
Two types of cells, namely cord lining epithelial cells (CLEC) and cord lining 
mesenchymal cells (CLMC) were isolated from the human umbilical cord as described 
previously by Prof. Phan Toan Thang from National University of Singapore (Kita et al. 
2010).  
This chapter describes the results of initial studies to characterize these cells. 
These include the basic morphological and growth characteristics and immunological 
markers expression.  
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4.2 Results 
4.2.1 Morphology and growth properties of cord lining cells 
 CLECs and CLMCs could be distinguished in culture with different 
morphologies--CLECs being polygonal and CLMCs being elongated and fibroblastic 
(Fig. 4.1A). Both CLECs and CLMCs exhibited proliferative potential in vitro. This was 
tested in plating efficiency using colony formation assay (Chapter 3, Methods 3.2.1). 
Both CLEC and CLMC cultures were able to form more than 20 colonies from 100 single 
cells over 14 days, demonstrating over 20% plating efficiency (Fig. 4.1B).  
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Figure 4.1 Morphology and colony formation of cord lining cells  
 
A.   CLEC             CLMC 
                                                                                         







          200 μm 








A. Phase contrast microscope view of the CLEC and CLMC in culture. The two cell types could 
be distinguished with different morphological features. B. Macroscopic view of CLEC and CLMC 
colonies stained with rhodamine. Pictures were taken on day 14 after 100 cells per dish were 
seeded. The unit of the rulers was cm.  
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4.2.2 HLA-G and HLA-E protein expression in CLECs 
Because of intention of using these cells in potential cell transplantation studies, 
the first set of molecular characterization was carried out to test the expression of HLA-G 
and HLA-E, which are non-classical MHC molecules (MHC-Ib) with 
immunosuppressive functions. Five primary cell lines each for CLECs and CLMCs from 
unrelated donors were studied.  
Significant levels of HLA-G proteins were detected in both cell lysates and 
culture supernatants of CLECs, suggesting that membrane and secreted forms were 
expressed. For HLA-G, a product of approximately 36 kDa (predicted to be isoform 5) 
was clearly evident in the cell lysates along with a secreted product of approximately 17 
kDa (predicted to be isoform 7) in culture medium (Fig. 4.2A). The full length isoform 
HLA-G1 were also detected in the cell lysates, with a molecular weight of around 39 kDa. 
But the levels of expression were quite low except in one of the five cell lines, compared 
to the positive control or the other isoforms described above.  
For HLA-E, a product of approximately 42 kDa was detected in cell lysates. No 
secreted isoforms of HLA-E were detected (Fig. 4.2A). 
The CLECs were also analyzed for the classical MHC I antigens HLA-A, B, C. 
Similar levels of HLA-A, B and C were detected in the vast majority of CLECs from all 
five donors (Fig. 4.2B).   
 
 79























A. Bands of HLA-G and HLA-E proteins were detected in western blot of CLEC protein samples 
from cell lysates and conditioned culture supernatants. B. Flow cytometry of HLA-A, B, C 
expression on the cell surface of CLECs. Results of five CLEC lines from different donors were 
shown. 
              CLEC 1            CLEC 2            CLEC 3            CLEC 4            CLEC 5 
JEG3 1 2 3 4 5 1 2 3 4 5
CLECs CLECs
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4.2.3 HLA-G splicing variants expressed in CLECs 
As multiple HLA-G isoforms were detected in western blot, RT-PCR was carried 
out to further examine the corresponding mRNA splice variants in the same set of CLEC 
cell lines. HLA-G has been described to have seven protein isoforms based on alternative 
splicing. Isoforms 1-4 are thought to be membrane bound and isoforms 5-7 are 
soluble/secreted (Fig. 4.3A) (Pace et al. 2006; Rebmann et al. 2007). The mRNA splice 
variants of HLA-G expressed by CLECs were identified using primer sets targeting 
specific exons/introns of the HLA-G gene by RT-PCR (Table 1). All of the CLEC lines 
expressed mRNA for HLA-G isoforms 1, 5 and 7. One cell line expressed isoform 3, four 
expressed isoform 2/4 and three expressed isoform 6. HLA-E mRNA was also detected 
consistently in the five CLEC lines (Fig. 4.3B). 
These results were consistent with the protein isoforms detected in western blot 
shown in the previous figure (Fig. 4.2A). 
 81
Figure 4.3 mRNA expression of HLA-G and HLA-E in CLECs 






























A. Schematic of HLA-G mRNA splice variants. B. RT-PCR results for HLA-G and HLA-E mRNA 
expression in five CLEC lines from different donors.  
                      CLECs 
JEG3 1 2 3 4 5
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4.2.4 HLA-G and HLA-E protein expression in CLMCs 
HLA-G and HLA-E expressions in CLMCs were also analyzed using western blot. 
Positive bands of two soluble HLA-G isoforms were detected in the culture supernatants. 
The smaller isoforms of 28 kDa is predicted to be HLA-G6. The bigger isoform should 
be HLA-G5, although the band size was slightly smaller than predicted (37 kDa). This 
difference in band size might be caused by post-translational modification.  
Similar to the CLECs, CLMCs also expressed HLA-E in the cell lysate but not in 
the culture supernatants (Fig. 4.4).  
Based on the findings that CLECs but not CLMCs express and secrete significant 
levels of HLA-G, most of the subsequent studies were carried out on CLECs. 
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A. Bands of HLA-G and HLA-E proteins were detected in western blot of CLMC protein samples 
from cell lysates and conditioned culture supernatants. Results shown were from five CLMC lines 
from different donors. 5-aza-2'-deoxycytidine  induced JAR cell line was used as positive control 
(Chapter 3, Materials 3.1.1.2).  
JAR 1 2 3 4 5 1 2 3 4 5
CLMCs CLMCs
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4.2.5 Epithelial and MHC class I markers in CLECs 
A panel of molecular markers was analyzed in CLECs using flow cytometry. The 
results demonstrated positive surface staining for HLA-A, B, C, the classical MHC class I 
molecules, while HLA-DR staining was negative. HLA-G and HLA-E were also detected 
using flow cytometry, which was consistent with the western blot and RT-PCR results. 
CLECs were positive for ICAM-1 (CD54), the intercellular adhesion molecule 1. 
They also expressed cytokeratins and adhesion molecules which are typical of epithelial 
cells. These include HCAM (CD44) and integrin β4 (CD104) (Fig. 4.5).  
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CLEC and CLMC, the two types of primary cells derived from human umbilical 
cord lining membrane, are different in morphology but share the same highly 
proliferative properties and colony forming efficiency.  
CLECs expressed MHC-I but no MHC-II antigens. Similar MHC expression 
pattern was reported in CLMCs (Kita et al. 2010). Expression of MHC-I is found in most 
of normal nucleated cells, which protects them from NK lysis.  
In CLECs, some individual variations in HLA-G mRNA splicing patterns were 
observed. Isoforms 1, 5 and 7 are the most prevalently and strongly expressed splice 
variants. Consistently, proteins of isoform 5 and 7 were detected in the cell lysate and 
conditioned medium respectively. 
In addition, CLECs expressed the epithelium specific intermediate filament--
cytokeratins, and adhesion molecules HCAM (CD44), ICAM-1(CD54) and integrin β4 
(CD104). This was distinct from the surface marker expression of CLMCs characterized 
and reported previously, which included positive expression of CD73, CD90, CD105, 
CD146,  α-smooth muscle actin and vimentin, but not desmin or cytokeratin (Kita et al. 
2010). 
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 Chapter 5   In Vitro Analysis of Cord Lining Cell Immunogenicity 
5.1 Introduction 
This chapter discusses studies using in vitro/ex vivo assays to assess the functional 
immunogenicity of CLEC and CLMC.  
The MHC profile of CLEC has been determined in chapter 4. CLEC expressed 
classical MHC-Ia antigens HLA-A, B, C like most adult nucleated cells. In addition, they 
also expressed the nonclassical MHC-Ib molecules HLA-G and HLA-E, the main 
function of which is thought to be immune suppression (Le Bouteiller et al. 2001; 
Sullivan et al. 2008). This chapter describes the results of the studies characterizing the 
immunoregulatory properties of CLEC.  
The mixed leukocyte reaction (MLR) is commonly used to mimic in vivo allograft 
recognition, effectively reflecting the histocompatibility between the donor and recipient 
of a graft (Knight et al. 2005). The effects of CLECs on T cell activation, regulatory T 
cell (Treg), T cell apoptosis and cytokine secretion were assessed.  
Inhibition assays performed by blocking HLA-G function were used to determine 
the role of HLA-G in the effects observed. Finally, the possibility of CLECs modulating 




5.2.1 Mitogen stimulated T cell proliferation  
Phytohaemagglutinin (PHA) is a potent mitogen for T-lymphocytes (Lindahl-
Kiessling et al. 1964; Janossy et al. 1971). It induces a strong proliferative response in the 
peripheral blood mononuclear cells, which can be measured by [3H] thymidine uptake. 
Equal volumes of conditioned culture supernatants from either CLECs or CLMCs were 
added into these PHA stimulated PBMC cultures (Chapter 3, Methods 3.2.5.1), 
resulting in significant decrease in cell proliferation.  
This effect was found with both CLEC and CLMC supernatants (Fig. 5.1A and 
B). The degree of inhibition was more pronounced with CLECs than with CLMCs 
(p=0.0111). CLECs from four donors caused 96.38+/-0.55% (mean+/-SEM, n=4) 
reduction in thymidine incorporation during 6 hours (Fig. 5.1A), while CLMCs from four 


























Human PBMCs were stimulated with the mitogen PHA. Cell proliferation was measured as 
tritiated thymidine incorporation. Stimulation index shows ratio of [3H] thymidine uptake of 
stimulated over unstimulated T cells (mean+/-SEM) in triplicate measurements. CLECs (A) or 
CLMCs (B) from four unrelated donors were tested by adding their conditioned culture 
supernatants into the PBMC cultures. P<=0.05 for both (A) and (B), by student’s t test with 
Bonferroni correction. 
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5.2.2 Mixed leukocyte reactions (MLR) 
Preliminary results from the mitogen assays indicated an immunosuppressive 
effect of the cord lining cells on T cell proliferation. The mixed leukocyte reaction (MLR) 
assay was employed to further examine and analyze this function. Compared to the 
mitogen PHA, the MLR utilizes allogeneic dendritic cells (DCs) (which are professional 
antigen presenting cells) as stimulus. This resembles the antigen presentation process in 
an allo-transplantation scenario. In the first set of experiments, equal amounts of CLEC 
or CLMC conditioned culture supernatants were added to MLR cultures. In the second 
set of experiments, CLECs or CLMCs were co-cultured with T cells and DCs in the 
MLRs to study the possible interactions between cord lining cells and immune cells. 
Using a transwell co-culture system, the study further investigated the involvement of 
soluble factors versus direct cell-cell contact.  
 
      5.2.2.1 Conditioned medium 
Purified T lymphocytes (mixture of CD4+ and CD8+ T cells at the physiological 
ratio of 2:1 in normal peripheral blood (Goff et al. 1985)) were activated by allogeneic 
DCs and proliferated over the 7-day reaction period. Conditioned culture supernatants of 
both CLECs and CLMCs from four different donors all caused significant reduction in 
[3H] thymidine uptake. The CLEC supernatants inhibited T cell proliferation in MLR by 
98.62+/-0.34% (mean+/-SEM, n=4) (Fig. 5.2A). The CLMC supernatants also 
consistently reduced MLR proliferation by 78.41+/-3.11% (Fig. 5.2B).  
The differences in the levels of inhibition would be consistent with the relative 
degree of HLA-G production by the two cell types (see section 4.2.2-4.2.4).  
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Purified T lymphocytes (CD4+:CD8+≈2:1) proliferated in response to allogeneic dendritic cells in 
mixed leukocyte reactions (MLR). Cell proliferation was measured in triplicates as tritiated 
thymidine incorporation. Stimulation index shows ratio of [3H] thymidine uptake of stimulated over 
unstimulated T cells (mean+/-SEM) in triplicate measurements. Conditioned culture supernatants 
from CLECs (A) or CLMCs (B) were tested. P<0.05 for both (A) and (B), by student’s t test with 
Bonferroni correction.  
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5.2.2.2 CD4+ versus CD8+ T cells 
A comparison between CD4+ and CD8+ T cells responses in MLRs was made. 
Conditioned culture supernatants of CLECs (from three different donors) were tested and 
all showed to inhibit CD4+ T cell proliferation (Fig. 5.3), similar to the inhibitory effects 
observed earlier with mixed CD4+ and CD8+ T cells. The inhibition of CD8+ T cell 
proliferation was not statistically significant, primarily because of the greater variability 
in CD8 responses in the control.  
Therefore, subsequent studies were carried out using purified CD4+ T cells in the 























CD4+ and CD8+ T cells were purified and separately stimulated in the MLR. Conditioned culture 
supernatants from four different CLEC cell lines were tested repeatedly in two independent MLR 
experiments. Stimulation index shows ratio of [3H] thymidine uptake of stimulated over 
unstimulated T cells (mean+/-SEM) in triplicate measurements. P<0.05 for CD4+ but not CD8+ 
conditions, by paired student’s t test with Bonferroni correction.  
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5.2.2.3 Co-culture  
In addition to the experiments done with conditioned culture supernatants, the co-
culture MLR was set up with the addition of the cord lining cells as third party cells. In 
this setting, the possibility of a dynamic cross-talk between the different cell types would 
be examined. The cord lining cells would be exposed to cytokines and cell-cell 
interaction from T-cells and DCs. 
To distinguish between the effects of soluble factors and direct cell-cell contact, 
the cord lining cells were co-cultured with the MLR, either directly or through a transwell 
(Fig. 5.4A). In the transwell co-culture, the DCs and T cells were cultured together as in 
normal MLR in the upper chamber and the cord lining cells were seeded in advance into 
the lower wells. The transwell system separated the different cell types by a porous 
membrane with 0.4 µm pore-size which allowed the diffusion of secreted factors while 
blocking cell-cell contact. The T cells were labeled with CFSE fluorescent dye prior to 
the MLR. Their proliferation was then assessed by flow cytometry. The CFSE dye would 
dilute into daughter cells upon each cell division, resulting in lower fluorescence intensity 
in the proliferated T cell population (Fig. 5.4B).  
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A. Schematic representation of direct and transwell co-culture systems. Brackets were used to 
indicate transwell co-culture as (T+DC)+CLEC. B. CFSE labelling was used to distinguish 
proliferating CD4+ T lymphocytes from resting cells. The fluorescent signals diluted during every 
cell division as the dye was divided between daughter cells. 
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Compared to when conditioned culture supernatants were added, the transwell co-
culture system tested the effects of diffusible soluble factors in the presence of mutual 
interactions between the cord lining cells and immune cells. The results from transwell 
co-culture experiments were consistent with those from conditioned supernatants 
experiments. Both CLECs and CLMCs co-cultured with DCs and CD4+ T cells through 
transwells caused significantly decreased levels of T cell proliferation, which could be 
shown as a reduced CFSEdimCD4+ population (Fig. 5.5A and B, respectively).  
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Figure 5.5 MLR co-cultured with cord lining cells 





















Flow cytometry analysis of the T cells after 7 days of MLR. CLECs (A) or CLMCs (B) were co-
cultured with the T cells and DCs through the transwell system. Proliferating T cells (divided) 
were CFSEdim and resting T cells (undivided) remained CFSEbright. Inhibition of T cell proliferation 
could be seen as blocking the shift from undivided to divided populations.  
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 The decrease in T cell proliferation (compared to control) induced by CLECs in 
co-culture MLR was statistically significant, in both direct (p=0.0011) and transwell 
(p=0.0003) co-cultures. Six independent MLR experiments were carried out using five 
different CLEC lines, of which one representative experiment was shown in Fig. 5.6A. 
The two types of co-cultures (direct and transwell) with CLECs did not show any 
significant difference in the inhibition of MLR proliferation (p=0.7713). 
 As an additional control, CLECs were co-cultured with CD4+ T cell alone 
(without DCs). This was to test the direct immune recognition between CLECs and CD4+ 
T cells. In both direct and transwell co-cultures, CLECs alone did not induce any T cell 
proliferation as compared to unstimulated controls (Fig. 5.6B).  
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Proliferation of CD4+ T cells was quantified as percentage of CFSEdimCD4+ cells among the entire 
CD4+ population. Brackets were used to indicate transwell co-culture as (T+DC)+CLEC or 
(T)+CLEC. A. Contour plots (CD4+ gated) of T cells harvested after 7 days of MLR. Results 
shown were from one representative experiment. B. Results from six independent MLR 
experiments (mean+/-SEM). Paired student’s t test with Bonferroni correction, ** two tailed p<0.01. 
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 To investigate the dose-function relationship in CLEC effected inhibition of 
allogeneic T cell response, the CLEC numbers in the co-cultures of MLR were diluted 2 
x, 5 x and 10 x to a final concentration of 5,000/well. The fewer number of CLEC co-
cultured with fixed number of T cells and DCs resulted in less inhibition of MLR 
proliferation. This dose-function relationship was similarly observed in both direct and 
transwell co-cultures (Fig. 5.7). In the transwell co-culture, there was significant 
inhibition (more than 50% decrease in [3H] thymidine uptake) with the addition of as few 

































CLEC numbers were titrated down against fixed numbers of T cells and DCs, to study the dose-
function relationship in the co-cultured MLR. Four different seeding density of CLECs from 50,000 
to 5,000 cells/well represented CLEC:T ratios of 1: 20, 1:40, 1:100, 1:200, respectively.  
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5.2.3 T cell apoptosis 
To investigate whether the decrease in T cell proliferation involved induction of T 
cell apoptosis by CLECs, Annexin V staining was used to detect apoptosis of T cells in 
the MLR. Annexin V binds with high affinity to phosphatidylserine residues externalized 
on the cell surface during apoptosis. The percentages of Annexin V+CD4+ cells in the 
CD4+ population were compared between the different experimental conditions (Fig. 
5.8A). The control MLR had around 20% of the CD4+ T cells stained Annexin V positive. 
Addition of CLECs to the MLR co-culture did not increase the apoptosis rate of T cells. 
Five independent experiments with four different CLEC lines were compared and no 
statistical significant difference was found with or without CLECs (Fig. 5.8B). The 
unstimulated T cells alone had a lower mean percentage of Annexin V+CD4+ cells 
compared to the other conditions, but the difference was not statistically significant 
(p>0.05).  
 103























A. Flow cytometry contour plots from one representative out of five independent experiments 
were shown. Double positive population in the upper right quadrant represented the apoptotic 
CD4+ T cell population from the MLR. B. Statistical analysis (paired student’s t test with 
Bonferroni correction) of apoptosis rates among the CD4+ T cells showed no significant difference 
between the different co-culture conditions. Results were shown as mean+/-SEM. N=5.  
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5.2.4 CD4+CD25highFoxp3+ regulatory T cells 
To investigate if the effect of CLECs on CD4+ T cell proliferation was mediated 
via regulatory T cells, the cells from the MLR were stained for CD4, CD25 and Foxp3. 
Regulatory T cells are a subset of T cells specialized in mediating immune tolerance, 
thereby suppressing both inflammatory and autoimmune responses (Jonuleit et al. 2003). 
The most studied Treg cells are known as naturally occurring Tregs, characterized as 
CD4+CD25highFoxp3+ cells (Hori et al. 2003).  
No significant increase could be detected in the numbers of CD4+ cells staining 
positively for CD4/CD25/FoxP3 in MLR cultures containing CLECs, compared to 
normal MLR control (p>0.05) (Fig. 5.9A and B). CD4+CD25highFoxp3+ cells were 
detected at similar frequencies in the MLR with and without CLECs.  
 There was a decrease in CD25+ staining for the T cells when CLECs were added 
(Fig. 5.9C). This was consistent with the decreased levels of proliferation described in 
previous sections, indicating decreased levels of T cell activation.  
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Figure 5.9 CD4+CD25highFoxp3+ Treg population in MLR 
A. 
 












A. The upper right hand quadrant shows the population of CD4+CD25highFoxp3+ Regulatory T 
cells. One of the three independent experiments was shown as a representative. B. Statistical 
analysis of the frequency of Treg cells among the CD4+ population showed no significant 
difference in the co-culture conditions tested. N=3. P>0.05 (paired student’s t test with Bonferroni 
correction). C. Frequency of CD25 positive cells among the CD4+ population.  
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5.2.5 Other regulatory T cells 
Other types of Treg cells without the mentioned CD4+CD25highFoxp3 markers 
have been reported (Chen et al. 1994; Groux et al. 1997). It is possible that some of these 
Treg populations can be induced through co-culturing with CLECs.  
One method of determining the existence of a suppressor T cell population is to 
transfer the cells onto a second MLR, as used by previous functional studies on Treg 
populations (Groux et al. 1997; Prevosto et al. 2007). T cells from a first MLR (T1) were 
harvested and added into the second MLR containing fresh T cells (T2) and DCs (Fig. 
5.10A). The DCs from the same donor were used in both MLRs to provide consistent 
antigenic stimuli. T1 cells co-cultured in the presence of CLECs during the first MLR 
showed a significant reduction from 56.16% to 28.74% in proliferation (Fig. 5.10B).  
 107



















A. Schematic representation of the consecutively performed first and second MLR experiments. 
First MLR was set up as previously described, with conditions of T1+DC and (T1+DC)+CLEC, 
which respectively generated T1 control cells and T1 CLEC-treated cells. Second MLR was set 
up at day 7 of the first MLR, with T1 cells transferred into fresh second MLR cultures. T2 but not 
T1 cells were labelled with CFSE. B. A parallel CFSE stained T1 MLR was performed to confirm 
inhibition of T1 proliferation during the first MLR. The CFSE-T1 cells were not used in secondary 
MLR.  
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In the second MLR, both the control and CLEC treated T1 cells enhanced T2 
proliferation. Nevertheless, the enhancement of T2 proliferation was significantly weaker 
when T1 cells had previously been co-cultured with CLECs during the first MLR (Fig. 
5.11A). The level of T2 proliferation increased with the proportion of T1 cells in the 
second MLR (Fig. 5.11B). This positive dose-effect indicated that the pre-activated T1 
cells generally had a stimulatory effect on the second MLR.  
The effects of a regulatory T cell population could not be detected, suggesting 
that CLECs did not induce a significant regulatory T cell phenotype with 
immunosuppressive functions. However, in this experimental setting, there was a small 
possibility that the immunosuppressive effects of a small regulatory T cell population 
might be masked by the presence of high numbers of activated T cells. Thus further 
experiments would be required to address this possibility.  
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Figure 5.11 T-lymphocyte proliferation in second MLR 























A. T1 cells from the 1st MLR were added to 2nd MLR at T1:T2 ratios of 1:10, 1:4, or 1:1 (T2 and 
DC numbers were fixed according to previously normal MLR settings). Both MLR experiments 
were done in duplicate culture wells. T2 cells were gated as CFSEdimCD4+ activated population 
(divided) and a CFSEbrightCD4+ resting population (undivided). Unstained T1 cells were CFSE-
CD4+. B. Percentage of proliferating cells among T2 was quantified as 
divided/(divided+undivided). 
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5.2.6 Cytokine profile of MLR  
Bioplex cytokine arrays were utilized to measure and compare the expression of 
pro- and anti-inflammatory cytokines in MLRs containing CLECs versus controls (Fig. 
5.12). CLECs cultured alone in routine propagation and maintenance did not secret 
detectable levels of any of the cytokines tested. Because of the wide variation between 
donors and individual experiments, each cytokine level was compared with the control in 
that same experiment. 
 CLECs co-cultured with the MLR caused significant decreases in the IL-5 levels, 
both at earlier time point (day 3) and at the end of the 7-day reaction. This effect was 
similarly observed in both the direct and transwell co-cultures.  
CLECs also caused siginificant decreases in cytokines IL-10, IL-13 and IL-17, in 
both direct and transwell co-cultures. But the decreases were only observed at the later 
time point of 7 days.  
CLECs caused decreases in IFN-γ at day 7 of MLR. But the decrease was 
statistically significant in transwell but not direct co-cultures. For IL-1β, CLECs caused 
increases at day 7, which was significant in direct but not transwell co-cultures.  
GM-CSF and TNF-α levels in the MLR did not change significantly upon the 
addition of CLECs.  
In summary, CLECs seemed to downregulate several pro-inflammatory cytokines 
of both the Th1 and Th2 pathways in the MLR, except for some increase in IL-1β.  
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Mean (SEM)     
pg/ml Day 3 Day 7 
IL-5 682.5 (574.5) 9579 (6474) 
  IL-10 13.0 (5.1) 71.5 (31.6) 
 
Cytokine concentrations were measured by multiplex bead suspension array (shown in the table 
above). Values of each experimental condition were normalized to the cytokine concentrations in 
the MLR control (T+DC). Fold changes were compared in the bar charts. *two tailed p<=0.05 by 









Mean (SEM)    
pg/ml Day 3 Day 7 
IL-13 6082 (5915) 7751 (4709) 
IL-17 24.9 (16.5) 62.2 (12.2) 
 
 
Cytokine concentrations were measured by multiplex bead suspension array (shown in the table 
above). Values of each experimental condition were normalized to the cytokine concentrations in 
the MLR control (T+DC). Fold changes were compared in the bar charts. *two tailed p<=0.05 by 
Wilcoxon signed-rank test with Bonferroni correction. Data shown was from three to five 









pg/ml Day 3 Day 7 
IFN-γ 6607 (6534) 2290 (1565) 




Cytokine concentrations were measured by multiplex bead suspension array (shown in the table 
above). Values of each experimental condition were normalized to the cytokine concentrations in 
the MLR control (T+DC). Fold changes were compared in the bar charts. *two tailed p<=0.05 by 














pg/ml Day 3 Day 7 
GM-CSF 297.9 (294) 267.5 (165.9) 
TNF-α 1776 (2104) 210.6 (127.7) 
 
 
Cytokine concentrations were measured by multiplex bead suspension array (shown in the table 
above). Values of each experimental condition were normalized to the cytokine concentrations in 
the MLR control (T+DC). Fold changes were compared in the bar charts. Data shown was from 
three to five independent experiments. 
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5.2.7 HLA-G functional studies 
5.2.7.1 shRNA inhibition 
To investigate if there was a significant role of HLA-G in the immunosuppression 
observed with CLECs, shRNA was used to knock down the HLA-G expression for a 
functional study. Five shRNA sequences targeting several different exons of the HLA-G 
gene were designed by algorithms of the RNAi Consortium (TRC) and were tested in the 
cell line JEG3 (Chapter 3, Materials 3.1.3.2). Three of the shRNAs had minimal effect 
on the mRNA levels of HLA-G isoforms as shown by RT-PCR (Fig. 5.13A). The other 
two shRNAs were able to knock down almost completely the expression of HLA-G2/4 
and HLA-G6 mRNAs, and significantly reduced the levels of HLA-G1 and G5 mRNAs. 
But HLA-G7 mRNA was hardly affected and was still highly expressed.  
 Western blot analysis of the shRNA transfected JEG3 cell confirmed that the gene 
silencing approach was not very successful. HLA-G5 and HLA-G2/4 proteins were 
detected in the cell lysates of JEG3. Two out of the five shRNAs blocked HLA-G3 and 
inhibited much of the HLA-G5 expression. But the remaining HLA-G5 was still present 
in considerable amounts compared to its original expression level (Fig. 5.13B).   
 In view of the inefficient RNAi suppression on the HLA-G species, another 
method of blocking HLA-G function was attempted—5.2.7.2. 
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Five ShRNA targeting the HLA-G gene (sequences given in Table 2) were overexpressed in 
JEG3 cells using lentiviral constructs. Uninfected cells and construct expressing scrambled non-
specific RNA sequences were used as controls. A. HLA-G mRNA in JEG3 was detected with RT-
PCR. B. Two HLA-G isoforms were detected in JEG3 cell lysates with western blot.  
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5.2.7.2 Blocking antibody 
 An alternative method was used for the functional study of HLA-G in CLECs. A 
blocking antibody against HLA-G was used which could bind to both its membrane and 
soluble isoforms and block its interactions with the receptors (Menier et al. 2003). CLEC 
conditioned culture supernatants treated with the blocking antibody lost most of its 
inhibition on the MLR. When blocking antibody was added to the CLEC conditioned 
supernatant prior to its addition to the MLR culture, the proliferation of CD4+ T cells was 
restored to about 80% of the normal MLR reaction, while an isotype antibody used in the 
control experiment had no effect (Fig. 5.14A). Control medium treated in parallel with 
the same antibody induced a small increase in T cell proliferation in the MLR.  
 In the MLR co-cultured with CLECs, addition of the anti-HLA-G blocking 
antibody did not show any effect on T cell proliferation (Fig. 5.14B). This was probably 
due to continuous secretion of HLA-G by CLECs in the co-cultures which might have 
exceeded the binding capacity of the antibody added.  
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A functional grade anti-HLA-G antibody 87G was added into MLR cultures for a functional study. 
A. Anti-HLA-G or isotype control antibody was pre-incubated with CLEC conditioned culture 
supernatants. Results shown were respresentative of two independent experiments. B. The 
blocking antibody (10 μg/ml) was added to the MLR cultures twice at day 0 and day 3, at the 
presence of co-cultured CLECs.  
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5.2.8 LPS induced dendritic cell maturation 
In addition to direct inhibition of T cell proliferation, CLECs might also possibly 
modulate immune responses via DCs. Here a DC maturation model using the 
lipopolysaccharides (LPS) was used to study the interactions between CLECs and DCs. 
Upon LPS treatment, surface expression of the adhesion molecule ICAM-1 and the co-
stimulatory molecules CD80, and CD83 were upregulated in the DCs. There was 
significant expression of the antigen presenting molecule HLA-DR in the control DCs in 
our culture conditions, which was not significantly upregulated by LPS. With regard to 
CD86 expression, there was a change in frequency distribution in the histograms upon 
LPS stimulation, although mean fluorescent intensity (MFI) did not increase significantly.  
Addition of CLEC conditioned supernatants into the DC culture did not induce 
any significant alterations upon the effects of LPS (Fig. 5.15).  
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HLA-DR, ICAM-1 and co-stimulatory molecules CD80, CD83, CD86 were used as molecular 
markers for DC maturation. No statistically significant effects were found with addition of CLEC 
conditioned culture supernatants.  
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5.3 Summary 
In this chapter, the results showed that conditioned medium from both CLECs and 
CLMCs inhibited PBMC proliferation induced by mitogens. The results also 
demonstrated that both CLMCs and CLECs inhibited T cell proliferation induced by 
allogeneic stimulation in the MLR. The inhibitory effects of CLECs were significantly 
greater than those of CLMCs. It had been shown in the previous chapter that CLMCs had 
very little HLA-G expression compared to the CLECs. This would be a possible reason 
for the differences in the immunosuppression observed in these studies.  
Results with CLECs indicated that the main responding cells in the MLR were 
CD4+ rather than CD8+ T cells, in concordance with reports that CD4 rather than the CD8 
lymphocyte is the principal responder to allogeneic stimuli in vitro (Prince et al. 1988).  
The immunosuppressive effects observed with the conditioned supernatants of 
cord lining cells suggested the existence of secreted factors acting on the T cells. This 
was supported by results from MLR co-cultured with cord lining cells through a transwell 
with diffusion of soluble molecules. Titration studies indicated that the immunoregulation 
observed was dose-dependent.  
CLECs co-cultured with the MLR caused significant decreases in several pro-
inflammatory cytokines, including IL-5, IL-13, IL17 and IFN-γ. But there did not seem to 
be a bias toward the Th1 or Th2 pathways. The decrease in IL-17 concentrations might 
indicate impairment in the differentiation of Th17 cells, which had the potential to impact 
on the development of alloreactive T cell responses (Kappel et al. 2009). Inhibition of 
Th17 cell differentiation and function has been reported as one of the mechanisms of 
MSC immune modulation (Ghannam et al. 2010).  
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The anti-inflammatory cytokine, IL-10, also decreased in MLR with the co-
culture of CLECs, indicating that immunosuppressive effects of CLECs were not 
mediated by IL-10. This was consistent with the observation that CLECs did not induce a 
significant suppressor T cell phenotype, because IL-10 has been implicated in the 
generation and function of regulatory T cells (Maynard et al. 2008). The Foxp3+ Treg 
might not be involved either, since the frequency of this Treg population did not increase 
at the presence of CLECs.  
The results also suggested that the inhibition of proliferation probably did not 
involve an induction of T cell apoptosis, and dendritic cell maturation was not affected by 
secreted soluble factors from CLECs.  
The functional studies demonstrated that HLA-G played a significant role in the 
immunoregulation of CLECs. When the CLEC conditioned culture supernatant was pre-
incubated with the blocking antibody against HLA-G, the immunosuppressive effect of 
CLEC was partially abolished. Similar role of soluble HLA-G5 has been previously 
reported in bone marrow derived MSCs (Selmani et al. 2008).  
In summary, the results in this chapter demonstrated that the CLECs inhibited 
both mitogenic and allogeneic T cell proliferations ex vivo. The inhibition was contact-









Chapter 6  Xenotransplantation of Cord Lining Cells 
6.1 Introduction  
In the previous two chapters, the immunoregulatory properties of CLECs have 
been characterized and defined.  
 In this chapter, studies were carried out to investigate if the immunoregulatory 
properties would lead to prolonged survival in vivo. The aim was to study the ability of 
these CLEC cells to survive and engraft for the purpose of transplantation.  
 Although there were some limitations in a xenotransplantation model, studies 
were performed to investigate the ability of CLECs to survive after transplantation into 
immunocompetent balb/c mice.  
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6.2 Results 
This section describes the use of a polymer membrane scaffold for the 
transplantation of CLECs, which would enable and facilitate the monitoring and retrieval 
of the transplanted cells. The CLECs were re-cultured after transplantation to 
demonstrate their viability. The survivability of the CLECs was compared to control 
human keratinocytes.   
 
6.2.1 Composition of the cellular graft 
An important aim of the exploratory studies was to identify and locate (and when 
possible retrieve) the CLECs after grafting into the recipient mice.  
The CLECs were infected with lentivirus to produce stable expression of a red 
fluorescent gene—DsRed2. CLECs to be transplanted were grown till confluency in a 
transwell culture chamber (Fig. 6.1A). The bottom of the insert made of a polyethylene 
terephthalate (PET) membrane could be excised and easily inserted into a subcutaneous 
pocket created during surgery. The PET membrane showed no autofluorescence and thus 
did not interfere with the detection of cells (Fig. 6.1B).  
The use of this method would also facilitate visualization of the grafted cells 
without sectioning or staining.  
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Figure 6.1 CLEC graft as a monolayer of cells on a PET membrane scaffold 







































A. Schematic of cord lining cells cultured into confluent monolayers in transwell culture insert. 
Bottom of the insert is a polyethylene terephthalate (PET) membrane. B. Cross section of a 
CLEC-DsRed2 graft before transplantation. It was composed of PET membrane with a layer of 
CLEC-DsRed2 cells grown on it. DAPI staining was used to label the cell nuclei.  
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6.2.2 Detection of CLECs after xenotransplantation 
Using fluorescent microscopy, CLEC-DsRed2 could be detected from the 
removed graft after 14 and 21 days of transplantation (Fig. 6.2A). No fluorescent signal 
could be detected in control PET membranes transplanted alone without cells.  
Cells after transplantation were no longer in monolayer but formed clumps. There 
was a decrease in size of the fluorescent clumps at the later time point of 21 days 
compared to 14 days. To verify that the fluorescence was from cellular structures, 
confocal microscopy was used to visualize the morphology of cells within the clump (Fig. 
6.2B). The CLEC graft was found to consist of intact cells rather than shattered cell 
debris.  
 129
Figure 6.2 Detection of CLEC-DsRed2 fluorescent clusters  
 
A.         14 days                       21 days        
             
                   200 μm 
B.         14 days                     21 days            
 












A. Fluorescent clusters were found on the membrane graft removed from the recipient mice after 
14 days and 21 days of transplantation. CLEC-DsRed2 could be identified from the graft as red 
fluorescent cells. B. Confocal microscopy was used to show cellular morphology in the 
fluorescent clusters.  
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6.2.3 Neovascularization of CLEC graft 
Blood vessels were observed in the graft after transplantation (Fig. 6.3A). These 
were found after 14 days post transplantation and were still present after 21 days. This 
was not observed in control PET membranes transplanted alone without cells. Unlike the 
cell clusters, none of the vascular structures exerted any fluorescent signal, indicating that 
they were most likely of host origin.  
Further evidence of neovascularization was provided by histology as blood 
vessels were identified near to the graft in H&E sections (Fig. 6.3Bi). Histological 
analysis also revealed signs of lymphocyte infiltration. Lymphocytes, small and densely 
stained cells with little cytoplasm, could be identified around the blood vessels and 
surrounding the graft site (Fig. 6.3Bii).    
Vascular endothelial growth factor (VEGF) is a known angiogenic factor 
(Carmeliet et al. 2000), and could possibly contribute to the increased formations of 
blood vessels in this instance. Therefore the expression of VEGF was assessed in CLECs. 
Positive VEGF mRNA expression was detected in all the CLEC cell lines tested (Fig. 
6.3C).   
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Figure 6.3 Vascularization of transplanted CLEC graft  
A.               14 days          21 days            
         
     500 μm     
B. i)          ii) 
                                        100 μm 







A. Blood vessels were observed on CLEC grafts upon removal from the mice on day 14 and day 
21. The PET membrane was wrapped in thin tissue and remained translucent under light 
microscopy.  B. Hematoxylin and eosin staining was used to analyze histology of the graft 
sections. Hollow parts were identified as blood vessels (i) or site of PET membrane (washed off 
during staining procedures) (ii). Graft from day 14 is shown. Pictures are representative of four 
mice. C. VEGF expression was detected in five CLEC lines using RT-PCR.  
        CLECs 
    1         2   3      4         5 
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6.2.4 Control primary keratinocytes 
The preliminary experiments described in earlier sections indicated prolonged 
survival of the cord lining cells in xenotransplantation. A second series of transplantation 
studies were carried out using CLEC-DsRed2, with addition of earlier time points and 
with a control cell type. 
Human primary keratinocytes were used as a control human epithelial cell-type to 
demonstrate the normal xenograft reaction by the immunocompetent balb/c mice. 
Keratinocyte is a classical epithelial cell type from the skin. This represents a cell type 
that is similar to the CLEC (CLEC could differentiate into keratinocytes in vitro (Ruetze 
et al. 2008)) but does not express HLA-G or HLA-E, as shown by flow cytometry (Fig. 
6.4).  
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Figure 6.4 HLA-G and HLA-E expression in CLECs and keratinocytes   
 


































Flow cytometric analysis of CLECs and keratinocytes for HLA-G and HLA-E expression. Results 
shown here were representative of five CLEC lines and three keratinocyte lines from different 
donors. *Cells were permeablized to stain intracellular antigens. 
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6.2.5 Prolonged survival of CLEC in contrast to keratinocytes 
The survival of red fluorescence tagged CLECs was compared to eGFP tagged 
keratinocytes in xenotransplantation model as described in 6.2.1. Earlier time points were 
included to match the fast response of xeno-rejection. Within 12 hours, a significant 
reduction in cell number was observed for eGFP tagged keratinocytes. By 48 hours, very 
few fluorescent cells could be detected. In contrast, CLECs transplanted in equivalent 
numbers in these experiments were found in red fluorescent clumps through all the time 
points up to day 14 (Fig. 6.5).  
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Figure 6.5 Detection of CLEC and keratinocyte fluorescence  
          








































Lentiviral transduced CLECs and keratinocytes, expressing DsRed2 and eGFP respectively, were 
visualised using fluorescent microscopy, before transplantation (in culture), and from excised 
grafts at three different time points after transplantation. Results shown were representative of 
four mice in each group.  
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6.2.6 Re-culturing of CLECs from graft 
In vitro cultures were re-established from grafted CLECs taken from Balb/C mice 
12 hours, 48 hours and 14 days post transplantation. This data would rule out the 
possibility of false positive results generated by fluorescence residues from dead cells or 
by neighboring murine cells that have internalized CLEC cellular debris (Fig. 6.6).  The 
re-cultured CLECs did not show any abnormal morphology or growth characteristics.  
By contrast, keratinocytes removed after 12 hours could not be re-cultured 
successfully.  
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Figure 6.6 Re-cultured CLECs from graft 











































Re-established CLEC cultures from the excised graft demonstrated the continuing viability of the 
transplanted cells. Not all the cells grown into cultures were fluorescent because adjacent murine 
cells were carried over with the graft.  
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6.2.7 CLEC and keratinocyte co-transplantation 
Co-transplantation of CLEC and keratinocyte cell mixture (at 1:1 ratio) resulted in 
significant improvement in survival of keratinocytes in the vicinity of CLEC. While few 
cells remained detectable after 48 hours after transplantation of keratinocyte alone (Fig. 
6.7A), keratinocytes transplantated together with equal numbers of CLECs could be 
found in large numbers at 12 hours as well as at 48 hours post-transplantation (Fig. 6.7B). 
Keratinocytes did not form clumps like the CLEC. Instead, the eGFP fluorescence from 




Figure 6.7 Survival of CLECs and keratinocytes in co-transplantation 










   






























 200 μm 
 
A. Keratinocytes transplanted alone. B. Co-transplantation of keratinocytes and CLECs in a 
mixture of 1:1. C. Lower magnification of the co-transplanted graft. Green fluorescence of the 
keratinocytes was found in proximity to the red fluorescent clusters of CLEC-DsRed2 cells.  
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6.2.8 Detection of CLMCs after xenotransplantation 
In addition to the CLEC xenotransplantation studies described, some studies were 
also carried out with CLMCs. eGFP tagged CLMCs could be visualized as green 
fluorescent cell clusters at 14 and 21 days after transplantation into immunocompetent 
balb/c mice (Fig. 6.8A). Confocal miscroscopy showed fibroblastic cell morphology 
which was characteristic of CLMCs (Fig. 6.8B). Smaller cell clumps were found at later 
time point of 21 days than at 14 days post transplantation.  
 The positive results indicated that the CLMCs also had an increase in survival in a 
xenotransplantation model compared to primary keratinocytes.  
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Figure 6.8 Detection of CLMC-eGFP fluorescent clusters 
A.     14 days              21 days     
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B.      14 days                     21 days      



























A. Fluorescent miscroscopy with CLMC-eGFP grafts at day14 and day21 after transplantation. B. 
Confocal microscopy of CLMC-eGFP grafts showing cellular morphology in the fluorescent 
clusters. Pictures are representative of four mice. 
 142
Blood vessels were observed in the CLMC graft through light microscope (Fig. 
6.9A) and in histological sections (Fig. 6.9Bi). Histology analysis also revealed signs of 
lymphocyte infiltration (Fig. 6.9Bii).    
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Figure 6.9 Vascularization of transplanted CLMC graft                     
A.                       14 days                     21 days             
                                                     500 μm                              
B. i)          ii)   












A. Blood vessels were observed on CLMC grafts upon removal from the mice on day 14 and day 
21. B. Hematoxylin and eosin staining was used to analyze histology of the graft sections. Graft 
from day 14 is shown. Pictures are representative of four mice.  
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6.3 Summary 
This chapter showed that the CLECs transplanted subcutaneously at only 0.6 
million cells per mouse, could be recovered after up to 14 days and recultured 
successfully. This was in contrast with human primary keratinocytes which were rapidly 
rejected and could not be identified after 2 days.  
Xenotransplantation in phylogenetically disparate species, such as between 
human and mouse, usually results in hyperacute rejection. This was observed in the 
control transplantation of the human keratinocytes, where by xenorejection destroyed 
almost all of the transplanted cells within 48 hours.  
Co-transplantation with CLECs greatly improved the survival of keratinocytes. 
This suggested that factors produced by CLECs could provide non-specific protection to 
other proximal human cell types and could delay their acute rejection. Combined with 
earlier in vitro results from chapter 4, these findings would be consistent with the 
hypothesis that one of the key factors probably was the soluble HLA-G secreted by 
CLECs. HLA-G has a well-established role in interacting with ligands on cells of the 
immune system including dendritic cells and T cells, exhibiting suppressive function on 
both (Chapter 2, 2.3.1.2.2). Hence HLA-G could possibly regulate mismatched MHC 
recognition and T cell response which are the key steps in acute rejection.   
It is noteworthy that all the experiments described in this chapter were performed 
in an immunocompetent xenotransplantation model without any exogenous 
immunosuppressant administration. CLECs have also been transplanted into 
immunodeficient mice in a collaborating laboratory. In these models, the CLECs 
engrafted and survived for four months without growing into tumors (Sivalingam et al. 
2010).  
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Chapter 7  Ex Vivo Insulin Gene Therapy Using CLECs 
7.1 Introduction  
The previous chapters demonstrated that CLECs possess immunoregulatory 
properties and could engraft and survive for prolonged periods after xenotransplantation 
into immunocompetent mice. This chapter utilized an animal model of disease to explore 
the therapeutic potential of CLECs. The streptozotocin (STZ) induced diabetic mouse 
model was chosen for this study. 
 The STZ induced mouse model was characterized by hyperglycemia and used to 
study type 1 diabetes (Sumi et al. 2004). Two approaches of treatment using CLECs were 
tested. First, an attempt was made to induce CLECs to differentiate into insulin producing 
cells in vitro and then transplant them into the diabetic mice. Second, the possibility of 
using CLECs in the delivery and expression of insulin as a candidate therapeutic 
transgene was investigated.  
To transplant insulin-secreting CLECs into the STZ induced diabetic mice, 
intraperitoneal injection was used instead of the PET membrane scaffold. Although the 
scaffold was used to transplant CLECs successfully for a survival study in the last chapter, 
it could only deliver very limited number of cells which might not meet the need of a 
therapeutic treatment. The intraperitoneal injection could deliver much larger numbers of 
CLECs into the peritoneal cavity and in the vicinity of the pancreas and liver. 
 




7.2.1 In vitro differentiation toward insulin-producing cells  
Based on Timper et al’s successful differentiation of adipose tissue-derived MSCs 
into insulin-producing cells (Timper et al. 2006), attempts were made to induce CLECs to 
differentiate using their previously reported protocol, in a medium supplemented with 
factors known to induce pancreatic or β-cell differentiation (Chapter 3, Methods 3.2.11).  
Using this protocol, mRNA expression of insulin was detected in CLECs after 7 
days of differentiation (Fig. 7.1A), while CLECs cultured in basal medium without the 
inducing factors did not express significant levels of insulin mRNA.  
To detect the insulin expression as a secreted protein, C-peptide ELISA was used, 
because exogenous insulin taken up by the cells from the culture medium could be 
confused with cellular insulin expression and could give false positive results (Rajagopal 
et al. 2003). C-peptide is a by-product in the biosynthesis of insulin and has a longer half-
life than insulin (Polonsky et al. 1984). It has been widely used in clinical monitoring of 
the insulin secretion.  
However, human C-peptide and human insulin could not be detected in the 
culture supernatants of CLECs after differentiation, indicating the absence of significant 
insulin secretion despite the demonstration of synthesis at the mRNA level (Fig. 7.1B).  
In summary, in vitro differentiation using this particular protocol did not 
successfully turn CLECs into insulin-secrecting cells. An alternative method to achieve 
insulin secretion was pursued, using CLECs that were transduced with lentiviral vector 
carrying human proinsulin gene.  
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A. RT-PCR with RNA extracted from control or differentiated CLECs. Cloned human insulin cDNA 
was used as positive control. β-actin was used as loading control. B. C-peptide ELISA with 
conditioned culture supernatants of CLECs control or differentiated. Human postprandial serum 
was used as positive control. Fresh medium was used as negative control. Three CLEC cell lines 
from different donors were shown, representative of 12 cell lines tested. 
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7.2.2 Transgene expression in vitro 
To use CLECs as cellular vehicle for the delivery of insulin transgenes, a 
lentiviral vector encoding a human proinsulin gene construct (Ren et al. 2007) was 
transduced into CLECs. The lentiviral vector contained a constitutive HIV/MSCV 
(human immunodeficiency virus/murine stem cell virus) promoter driving the human 
insulin gene and an internal ribosome entry site (IRES) linking to eGFP, which served as 
a marker for successfully transfected/engrafted cells (Fig. 7.2A). The transgene human 
pro-insulin was modified to allow cleavage by the ubiquitously expressed protease, Furin 
(Groskreutz et al. 1994; Steiner 1998).  
This lentiviral transduction resulted in the efficient and stable expression of 
human insulin and eGFP in CLECs (CLEC-INS for short). Lentiviral infection led to 
chromosomal integration of the transgenes and the HIV/MSCV promoter drived their 
constitutive expression. After 10 culture passages post-transfection, CLECs remained 
strongly positive for GFP as shown by both immunofluorescence microscopy (Fig. 7.2Bi) 
and flow cytometry (Fig. 7.2Bii).  
Human C-peptide was detected in the culture supernatants of CLEC-INS by 
ELISA (Fig. 7.2C), indicating that these cells secreted human insulin. 
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A. Schematic of the lentiviral construct with human proinsulin and eGFP genes. B. i) CLEC-INS 































           














B. ii) CLEC-INS analyzed with flowcytometry, at 10 passages after infection. C. C-peptide ELISA 
with CLEC and CLEC-INS conditioned culture supernatants (48 hour incubation). N.D.=Not 
detected.  
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7.2.3 Localization of CLEC graft 
 Ten million insulin-expressing CLECs were transplanted into each STZ induced 
diabetic mouse. The injection was done intraperitoneally to deliver the cells proximal to 
the anatomical position of the pancreas. This also allowed injection of large number of 
cells with minimal surgical invasion.  
Necropsy of the mice three weeks post transplantation revealed an opaque cluster 
of cells around the pancreas of the CLEC-INS (6 out of 8 mice) group and the CLEC 
control group (7 out of 8 mice) but not in the medium control group (Fig. 7.3). In a rare 
case (1 out of 8 mice in the CLEC-INS group), clusters were found at the liver as well as 
at the pancreas of the recipient, with similar appearance, size and histological 
morphology. These clusters varied in size, some as big as a few millimeters in size.  
To examine the presence of CLECs in these clusters, the opaque tissues together 
with the mouse pancreas were analyzed with immunohistochemistry.  
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Arrow shows the location of opague cluster of cells. Pictures were taken immediately after 




























Arrows show the location of opague cluster of cells. Pictures were taken immediately after 

























Arrows show the location of opague cluster of cells. Pictures were taken immediately after 
euthanasia and before graft removal. Mice were euthanized 22-23 days after cell injection unless 
otherwise stated. 
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7.2.4 eGFP expression in vivo 
 To verify whether the cluster of cells found at the host pancreas were transplanted 
CLECs, they were harvested together with the pancreatic tissue for histological analysis.  
Anti-GFP antibody was used to detect transgene expressions in vivo. eGFP-expressing 
cells were identified by the sporadic red-brownish staining inside the cluster of cells 
attached to the mouse pancreas (Fig. 7.4). This demonstrated that the cell cluster was 
conprised of CLECs and the CLECs expressed transgenes in vivo.  
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Paraffin section of CLEC cluster together with mouse pancreas tissue, stained with anti-GFP, and 
then counterstained with hematoxylin. Red-brownish staining indicated positive results. Picture 
shown was graft removed at day 5.  
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7.2.5 Histology of engrafted CLEC cluster 
Almost all of the cells in the cluster were human vimentin-positive, confirming 
the identity of the GFP-positive cells to be of human origin (Fig. 7.5A). Moreover, the 
vimentin-positive cells could be found in large numbers all over the cluster from grafts 
removed as long as 22 days after transplantation (Fig. 7.5B), while GFP-positive cells 
were detected in a portion of cells (Fig. 7.4). This was consistent with the previous in 
vitro results that more than 80% but not all the CLECs expressed eGFP (Fig. 7.2Bii).  
  Only a few of human vimentin-negative cells could be found among the 
positively stained cells. These could be mouse cells infiltrated into the CLEC graft. They 
were few in number and did not resemble either endothelial cells or lymphocytes (Fig. 
7.5B). The clusters had very defined rounded shapes and had no mouse fibroblasts 
surrounding the periphery. The border between the cluster and adjacent pancreatic tissue 
was clear and smooth with no signs of invasion.  
Certain morphological changes were observed in vivo with the cells in the cluster. 
Early after transplantation (5 days), cells were round and packed closely in the cluster. 
The cluster was big and had a dense and darker center with fragmented cellular materials 
suspected to be a sign of necrosis (Fig. 7.5Ci). At 22 days after transplantation, cells 
were found distributed loosely in the cluster, with much more intercellular space filled 
with extracellular matrix materials. Cell morphology were found to be no longer round 
but fully stretched out (Fig. 7.5Cii).   
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Paraffin section of CLEC cluster together with mouse pancreas tissue, stained with human 
specific anti-vimentin, and then counterstained with hematoxylin. Red-brownish staining indicated 
positive results. Picture shown was graft removed at day 5.  
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Paraffin section of CLEC cluster together with mouse pancreas tissue, stained with human 
specific anti-Vimentin, and then counterstained with hematoxylin. Red-brownish staining indicated 
positive results. Picture shown was graft removed at day 22 and representative of grafts 


























Higher magnification images of Figure 7.5A and B.  
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7.2.6 Serum glucose levels and body weights of recipient mice 
 The blood glucose levels in CLEC-INS treated mice stabilized at approximately 
22 mM over 18 days, in contrast to the control group with constantly higher average 
levels during this period which peaked at around 32 mM. This difference was statistically 
significant by analysis with general linear model for repeated measures (Dunnett’s test 
p=0.002). There was no significant difference between the medium control group and the 
uninfected CLEC control group (Dunnett’s test p=0.375) (Fig. 7.6A).  
Body weights of the mice were monitored during the experiments. They were 
compared to each individual mouse’s weight one day before the transplantation. Mice 
from all three groups lost weight over time due to STZ-induced diabetes-like symptoms. 
The mean of percentage weight of the medium control group stayed lower than the two 
CLEC-treated groups in all the time points over 17 day, but was found to be not 











A. Serum glucose levels of CLEC or control medium injected diabetic mice, starting from the 
injection day. B. Percentage of weight for the CLEC or control medium injected diabetic mice, 
normalized against each mouse’s weight one day before injection. Data is shown as mean+/-
SEM. N=5 for medium control group, n=8 for CLEC control group, n=8 for CLEC-INS group.  
 Medium Ctrl








7.2.7 Histology of mouse pancreas 
 To rule out the possibility of islet regeneration, anti-insulin antibody was used to 
stain mouse islets from the pancreatic tissues. Islets of the normal healthy mice had an 
intact morphology and showed strong positive staining for insulin. In the STZ induced 
diabetic mice which were used for transplantation experiment, very few islet cells could 
be detected as shown by insulin staining (Fig. 7.7A). Islets of the STZ induced diabetic 
mice had much less insulin expression compared to the healthy controls. Cells in the 
islets which did not stain for insulin could be β-cells destroyed by the toxicity of STZ. 
Examination of the mouse pancreas earlier after STZ injection (5 days after cell 
transplantation) or at the end of the transplantation (22 days) did not show any 
differences in the number of islets detected or the lack of insulin staining. This indicated 
that islet regeneration did not take place during the period of transplantation (Fig. 7.7B).  
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Figure 7.7 Insulin staining of mouse pancreas 
 















A. Paraffin sections of mouse pancreas stained with anti-insulin. Red-brownish colors indicated 
positive staining. Normal healthy mouse pancreas was taken from an untouched mouse from the 
same batch. STZ treated mouse pancreas was taken from CLEC injected mice after graft removal. 




















































Insulin stained islets found occasionally in STZ treated mice. Grafts removed after 5 days or 22 
days after the cell injection were compared.  
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7.2.8 Insulin staining  
The previous sections showed results demonstrating the CLECs engrafted in vivo 
and regulated glucose levels in the STZ induced diabetic mice. However, the CLEC 
clusters were not stained with anti-insulin antibody (Fig. 7.8).  
This was probably due to the anti-insulin antibody used to detect human insulin in 
the infected and grafted cells. The antibody was routinely tested in pancreatic tissue 
sample consisting of intracellular insulin granules. There were at least two differences 
that could account for the lack of staining in the CLECs: first, transgene expression of 
insulin in CLEC might have resulted in diffused cellular distribution and constant 
release/secretion of the protein instead of storage granules like in β-cells. Second, this 
particular antibody might be sensitive to the furin modification and has a decreased 
affinity with the recombinant insulin protein. 
The above hypothesis was supported by in vitro staining of the transfected CLEC-
INS cells. These cells strongly expressed and readily secrected human C-peptide into the 
culture supernatants, as shown in an earlier section of this chapter (Figure 7.2C). But the 
anti-insulin antibody stained very few of these cells although anti-GFP antibody showed 
strong positive staining (Figure 7.9). Based on these results, the lack of insulin staining 
in vivo was more likely due to lack of insulin storage granules in the cytoplasm.  
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Paraffin section of CLEC cluser together with mouse pancreas tissue, stained with anti-insulin. No 
positive staining could be detected in the cluster.  
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Figure 7.9 GFP and insulin staining of cultured CLEC-INS cells 
 
  



































             
 





Cultured CLEC-INS cells were cytospinned onto glass slides and stained with anti-GFP or anti-
insulin. Red-brownish colors indicated positive staining.  
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7.3 Summary 
In this chapter, attempts were made to use CLECs for the treatment of type 1 
diabetes in a STZ treated mouse model.  
The first approach was to differentiate CLECs in vitro toward the pancreatic 
lineage and into insulin-producing cells. However, the differentiation protocol induced 
low levels of mRNA expression but not secretion of insulin protein in the CLECs.  
The other method was to transfer the human proinsulin gene into the CLECs 
using lentiviral construct. This approach resulted in stable, integrated transgene 
expression of insulin and eGFP.  
The infected cells remain more than 80% positive for GFP 10 passages after 
infection, indicating a high integration rate and stable in vitro expression. Human C-
peptide was detected in culture supernatants, validating the CLEC-INS’s ability to secrete 
processed and mature insulin.  
After injection into the peritoneal cavity, CLECs aggregated at the pancreas of the 
STZ induced diabetic mice. This allowed graft retrieval after the transplantation. 
Histological analysis showed that CLECs formed a cluster in vivo and the cluster was 
usually found attached to the mouse pancreas. Human specific vimentin antibody stained 
almost all the cells in the cluster but not any of the adjacent mouse tissues. Anti-GFP 
staining also stained cells in the cluster, indicating expression of transgenes in vivo.  
The treatment effect of CLEC-INS was seen in a significant decrease in serum 
glucose levels in the STZ induced diabetic mice after cell injection, compared to control 
groups injected with medium control or CLEC control.  
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In summary, the ex vivo gene therapy using CLECs for the delivery of insulin into 
STZ induced diabetic mice showed improvement in their diabetic control. However, 
euglycemia was not achieved. This might be due to a few factors.  
First, it might be explained by the low efficacy of human insulin in mice (Pepper 
et al. 2009). 
Second, the constitutive expression of insulin by CLECs lacked the 
responsiveness to glucose, and thus would be secreted in a constant steady level only.  
Finally, the number of cells injected, or cells that survived in the peritoneal cavity, 
may have been inadequate, as suggestd by the absence of detectable levels of C-peptide 
from the serum of CLEC-INS recipient mice. As this was a proof-of-principle study, 
further dose-response studies would be necessary to answer the question of optimal cell 
numbers.  
 The aggregation of CLECs at the pancreas might be important in this study as it 
facilitated the access of secreted insulin to the host portal circulation. This was also 
interesting because cells injected in suspension are usually expected to disperse freely 
inside the peritoneal cavity. One possible explanation for this behaviour/pattern was 
migration of the cells to injury sites as part of the regenerative process (Bittira et al. 2003; 
Natsu et al. 2004; Ji et al. 2004). The pancreas in this model represented a site of injury, 
since STZ conveyed acute toxicity of the islet β-cells and caused cell death in the 
pancreatic tissue. Maybe due to the short period of transplantation in this study, no signs 
of islet regeneration have been observed. The chemotaxis of CLECs would be an 




Chapter 8  Discussion and Conclusion 
This thesis entails the first detailed study on a novel cord lining derived epithelial 
cell population obtained from the human umbilical cord. In this study, the immunological 
properties of cord lining epithelial cells (CLECs) have been comprehensively 
investigated in vitro, and some preliminary studies have also been carried out in vivo.  
   
8.1 HLA-G expression and immunosuppressive functions 
The present study presented data on the analysis of all the seven isoforms of 
HLA-G in CLECs. This has added new knowledge about the endogenous expression of 
HLA-G in this physiologically relevant primary cell type. The alternatively spliced 
transcripts of HLA-G have been investigated in the trophoblast and artificially transfected 
cell lines (Hviid et al. 1998), but previous investigations on other cell types used for 
transplantation studies have not studied HLA-G to the same extent. There have been 
reports of HLA-G expression in MSCs derived from bone marrow (Selmani et al. 2008), 
Wharton’s jelly (La Rocca et al. 2009) and amniotic membrane (Tsuji et al. 2010). 
However, these studies either focused on the two full length isoforms or only 
distinguished between membrane and soluble forms of HLA-G. There have also been 
some indications that human amniotic epithelial cells (hAECs) may also express HLA-G, 
as HLA-G has been detected in the amniotic epithelium region of amnion tissues 
(Hammer et al. 1997) and in mouse liver after infusion of hAECs (Manuelpillai et al. 
2010). However, HLA-G expression in isolated hAEC cell lines has not been 
characterized in vitro.  
The present study has demonstrated, using a functional assay, that secreted 
soluble HLA-G makes a significant contribution to the immunoregulatory properties of 
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CLECs. A similar functional study of the secreted HLA-G has been reported for bone 
marrow MSCs (Nasef et al. 2007) and the results were consistent with this current CLEC 
study. These are to date the only two cell types in which HLA-G has been functionally 
demonstrated to be directly linked to their immunoregulatory properties. While bone 
marrow MSCs have been studied in therapy-resistant severe acute graft versus host 
disease, treatment of rejection of organ allografts and autoimmune disorders (Le Blanc 
2006), the results in this thesis suggest that CLECs may potentially be useful in a similar 
way. Being a readily available cell source which can be obtained at higher quantities with 
less invasive procedures than the bone marrow MSCs, CLECs may be worth further 
exploration in similar clinical situations. 
The immunological properties of CLECs characterized in this study are consistent 
with reports on other types of extraembryonic tissue derived cells. Many of these cells, 
and CLECs, consistently express MHC-I but not MHC-II antigens (with the exception of 
some umbilical cord perivascular cells, as reviewed in 2.3.6), and inhibit lymphocyte 
proliferation in vitro, and thus this might be a common feature associated with their 
origin from the maternal/fetal interface.  
However, some differences between the current results and previous reports on 
MSCs have been observed with regard to the mechanisms of immune modulation. 
Results from the current study did not support induction of T cell apoptosis, induction or 
expansion of regulatory T cells and inhibition of DC maturation as possible mechanisms 
by which CLECs inhibited T cell proliferation. These mechanisms have been shown to 
mediate the immunomodulatory functions of bone marrow stem cells (Jiang et al. 2005; 
Plumas et al. 2005; Selmani et al. 2008). Amniotic membrane MSCs have also been 
shown to block differentiation and maturation of monocytes into dendritic cells (Magatti 
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et al. 2009). Direct comparative studies might be necessary to confirm these differences, 
which might indicate distinct immunological pathways involved in the immune 
regulation of the respective cell types.  
 
8.2 Prolonged survival in xenotransplantation 
This study also investigated the immunogenicty of CLECs in an in vivo model, 
using xenotransplantation into immunocompetent mice. Results have indicated superior 
survivability of CLECs, based on comparison to keratinocytes as a control primary 
human epithelial cell. Previous in vivo studies with transplantable stem cells mainly 
aimed to investigate the therapeutic effects in a diseased animal model and usually 
employed additional measures to avoid immune rejection of the transplanted cells. This 
current study was purely dedicated to the test of immunogenicity in vivo, using host 
animals which were fully immunocompetent, with no immunosuppressant administration, 
and at a transplantation site which was accessible to the host immune system.  
In addition to the detection of fluorescent markers, the CLECs could be retrieved 
from the xenograft, and could be recultured and maintained their morphology and 
transgene marker expression. Most of the previous studies on in vivo survival of stem cell 
transplantations have used the persistence of biochemical markers to indicate survival of 
the transplanted cells. These have included detection of transplanted-cell specific 
proteins/DNAs or pre-labeled molecular markers, to demonstrate survivability. One of 
the major limitations of these findings has been the possibility of the persistence of these 
markers in dead (but not degraded) cells or the possible internalization of cellular debris 
by adjacent host cells. The current study presented in this thesis has eliminated these 
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possibilities by retrieving these cells from the mice, and then establishing viable cell 
cultures from these retrieved cells.  
Further more, CLECs delayed the rejection of keratinocytes and extended their 
survival when co-transplanted, indicating an ability to protect adjacent human cell types 
that would otherwise be rejected if transplanted alone. This protective effect might have 
been mediated via secreted factors and modulation of the local microenvironment. These 
positive in vivo results support the conclusion that CLECs have the ability to mediate 
immune responses. 
Co-transplantation of bone marrow derived mesenchymal cells together with 
therapeutic cells/tissues has been attempted as a strategy to promote engraftment, 
vascularization and to modulate host immune responses. The supportive role of MSCs in 
hematopoietic stem cells ex vivo culture and in vivo engraftment has been relatively well 
studied. There have also been reports of the beneficial effects of MSC in co-
transplantation with islets (Solari et al. 2009), cardiomyocytes (Min et al. 2002) and skin 
grafts (Bartholomew et al. 2002) as a third party cell. It has been postulated that the 
prolonged survival of grafts in these studies might at least in part be attributed to the 
immunomodulatory functions of MSCs.  Preliminary results from the current study may 
indicate the potential use of CLECs, as an alternative source to MSCs, in this co-
transplantation strategy.  
 
8.3 Application in ex vivo gene therapy  
The final portion of this thesis was a pilot study investigating the potential 
application of CLECs in treatment of diabetes using an STZ-induced diabetes mouse 
model. The CLECs were transduced in vitro to express human insulin and significantly 
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lowered serum glucose levels of the STZ induced diabetic mice. Further studies on the 
optimization of the dosage and site of transplantation will certainly be required, but the 
current results have provided a proof-of-principle for the potential use of CLECs as a 
cellular vehicle for the delivery of therapeutic transgenes.  
This is one of the first few studies to date which have investigated the application 
of fetal/neonatal stem cells as transgene carriers in vivo. A similarly study using a 
different transgene integration approach and demonstrating significant therapeutic effects 
in a mouse model of hemophilia has been reported recently by collaborators, using these 
same CLECs (Sivalingam et al. 2010). These results, taken together, consistently indicate 
that CLECs can be considered a candidate cell source for ex vivo gene therapy.  
Another interesting observation in this final experiment was the aggregation of 
the transplanted CLECs at the region of the recipient STZ damaged pancreas. 
Interestingly, a similar phenomenon was reported in a preliminary ex vivo gene therapy 
study using Wharton’s jelly MSCs, which described their selective migration to tumor 
tissues in SCID mice (Rachakatla et al. 2007). Although the mechanism has not been 
investigated, this was suggested to be associated with the MSCs’ stromal cell phenotype, 
because migratory and chemotactic properties have been repeatedly reported for bone 
marrow derived MSCs (Chamberlain et al. 2007). However, results from the current 
study show a very similar property to that description of the MSCs. The possibility of 
random coincidental localization is unlikely, since cells injected in suspension should 
disperse in the peritoneum, as has been reported in a xenotransplantation study of human 
adipose tissue derived MSCs (Meyerrose et al. 2007). They reported a ubiquitous pattern 
of tissue distribution after intraperitoneal injection of the MSCs into immuno-deficient 
mice. The findings in this present thesis suggest the possibility of an active migration of 
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CLECs which might have been mediated by factors released by the STZ-induced injury 
of pancreatic islets. This would be extremely interesting to investigate further. 
 
8.4 Conclusion 
 In conclusion, this study has investigated the properties of the novel cord lining 
derived epithelial cells in detail, and demonstrated the potential of these cells as a vehicle 
for gene therapy. The expression and secretion of HLA-G with its immunosuppressive 
function, presented in this study, would give these cells an advantage over other cells that 
do not express HLA-G. 
 In addition, CLECs have advantages in being an easily accessible, abundant in 
supply, and ethically uncontroversial source of transplantable cells. It is readily available 
with a high rate of isolation and high yield. It can be easily propagated and transfected in 
vitro/ex vivo. Combined with the immunological properties including HLA-G expression 
and modulation of immune responses in vivo and in vitro, CLECs hold great potential for 
application in an allotransplantation scenario. Being a novel cell type, studies on CLECs 
are still very limited and some future studies are recommended. 
 
8.5 Future Work 
Future studies that would be of great interest in helping with the understanding of 
these cord lining epithelial cells, and helpful in realizing some of the potential 
applications would include: 
1. A comparison of these cells with amniotic membrane derived epithelial cells, 
which have been reported to have multipotent stem cell characteristics, and which have 
not been studied with regard to HLA-G. 
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2. The stability of HLA-G (and its isoforms) expression in CLECs would be very 
important and should be studied in detail. Since HLA-G has been shown a key molecule 
mediating the immunosuppression of CLECs, it would be important to monitor the 
changes in HLA-G expression during in vitro propagation, genetic manipulation, 
cytokine stimulation, and after in vivo transplantation. This would have important 
implications in the maintenance or possible loss of immunoregulatory functions of the 
CLECs.  
3. CLECs can potentially be used for studies of HLA-G signaling and regulatory 
pathways. This may serve a physiological model instead of the recombinant HLA-G 
protein widely used in previous studies. For this purpose, CLECs also have the advantage 
over trophoblasts in that a primary cell line of CLECs can be consistently maintained 
long-term in culture without the need of transformation or immortalization.  
4. The potential migratory properties of CLECs and the phenomenon of CLECs 
aggregating at an injured site that were observed in this study could be investigated 
further. The possibility of the existence of chemotaxis receptors and their expression, if 
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